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ABSTRACT 
The rapid response of mitochondria to cellular Ca
2+
 signals depends on their close 
proximity to the ER, allowing them to sense microdomains of high [Ca
2+
] meeting the low affinity 
of the mitochondrial Ca
2+
 uniporter (MCU) of the inner membrane. Recent work has demonstrated 
that the subcellular fraction denominated Mitochondria-Associated Membranes (MAMs) may 
correspond to this signaling domain, as in electron micrographs it shows the apposition of the two 
organelles and it is enriched in Ca
2+
 channels and regulatory proteins. The Transforming Growth 
Factor-β (TGF-β) family consists of more than 30 different but structurally related polypeptides, 
which are known to have crucial roles in the regulation of cell proliferation, differentiation and 
apoptosis. The downstream effectors of TGF-β signaling are intracellular proteins called Smads 
that hetero-oligomerize after phosphorylation and subsequently migrate into the nucleus to 
influence gene expression. While much progress has been made in understanding TGF-β 
regulation of gene expression, the subcellular distribution of Smad proteins and their nuclear-
independent activity are still incompletely understood. 
We have investigated the effect of the TGF-β signaling on intracellular Ca
2+
 homeostasis. 
The results showed that Smad2/3, both in HeLa cells and in liver preparations, are present in 
mitochondria, with a specific enrichment in the MAM fraction. Such a distribution may underlie a 
direct, transcription-independent role in the modulation of the ER/mitochondria Ca
2+
 cross-talk. 
This possibility has been directly investigated using aequorin-based recombinant probes targeted 
to the mitochondria, the ER and the cytosol. Specifically, we observed that treatment with 
inhibitors of the TGF-β receptor family, such as SB431542 and Dorsomorphin (Compound C) 
reduces agonist-dependent increases of mitochondrial Ca
2+
 concentration [Ca
2+
]m, while leaving 
the cytosolic responses unaffected. The effects were observed also upon inhibition of protein 
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synthesis, thus ruling out the possibility that they are due to alterations of the expression levels of 
Ca
2+
 transporters. The same effects were observed by shRNA silencing of Smads, thus involving 
these TGF-β transducers in the mitochondrial effects. Work is currently under way to identify the 
mechanism of the Ca
2+
 signalling alterations (intrinsic desensitization of the MCU, reduction of the 
electrochemical driving force, etc.). 
Altogether, these data demonstrate that also the TGF-β signaling pathway converges on 
mitochondrial checkpoint, clustering intracellular transducers in critical signaling domains and 
modulating Ca
2+
 loading and the sensitivity to growth-promoting and apoptotic challenges.  
 
 
 
 
 
 
 
 
 
 
 
 
  
3 
 
ABSTRACT (italiano) 
La rapida risposta dei mitocondri ai segnali Ca
2+ 
intracellulari dipende dalla loro prossimità al 
Reticolo Endoplasmatica che permette loro di sentire microdomini caratterizzati da elevate 
concentrazioni di Ca
2+ 
che spiegano come questi organelli possano accumulare transitoriamente 
grandi quantità di calcio nonostante sia nota la bassa affinità con cui il trasportatore mitocondriale 
(MCU) sia in grado di muovere lo ione attraverso il doppio strato della membrana. Recentemente 
è stato dimostrato che la frazione subcellulare denominata MAM (Mitochondrial Associated 
Membrane) può corrispondere al dominio funzionale poiché in studi morfologici precedenti è 
stata osservata la giustapposizione dei mitocondri al Reticolo Endoplasmatico e inoltre tali regioni 
risultano arricchite di canali Ca
2+  
e proteine regolatrici. La famiglia del Transforming Growth 
Factor-β (TGF-β) consiste in più di 30 membri diversi, polipeptidi  strutturalmente correlati con 
note proprietà regolatorie in processi cellulari come la proliferazione, il differenziamento e 
l’apoptosi. Gli effettori a valle del TGF-β sono proteine chiamate Smads che etero-oligomerizzano 
in seguito a fosforilazione e migrano nel nucleo dove regolano l’espressione genica. Mentre sono 
stati fatti molti progressi verso la comprensione dell’attività nucleare del TGF-β, la distribuzione 
subcellulare  e l’attività nucleo-indipendente delle Smads risulta ancora piuttosto sconosciuta. In 
questo lavoro è stato investigato il ruolo di TGF-β nell’omeostasi intracellulare del Ca
2+ 
 . 
I risultati dimostrano una localizzazione subcellulare delle Smads nei mitocondri sia in HeLa che in 
preparazioni da fegato di topo, mostrando un particolare arricchimento a livello delle MAMs. 
Questa distribuzione può suggerire un ruolo trascrizione-indipendente di queste proteine nella 
regolazione del cross-talk tra Reticolo Endoplasmatico e mitocondri. Tale ipotesi è stata testata 
direttamente grazie all’utilizzo di sonde per il Ca
2+
 che sfruttano la tecnologia dell’aequorina, 
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targhettate in modo specifico ai mitocondri, al Reticolo Endoplasmatico e al cytosol. Precisamente 
è stato osservato che  l’utilizzo di inibitori di isoforme diverse del recettore per il TGF-β, come la 
molecola SB431542 e Dorsomorphin (Compound C) riduce l’ingresso di calcio nei mitocondri, 
lasciando inalterata la risposta nel cytosol. La stessa osservazione è stata fatta in presenza di un 
inibitore della sintesi proteica, eliminando così la possibilità che tale effetto fosse il risultato di 
un’alterazione nei livelli di espressione dei trasportatori mitocondriali del Ca
2+
. Lo stesso effetto è 
stato osservato mediante l’uso di ShRNA capaci di silenziare diverse isoforme di Smads.  
La comprensione del meccanismo alla base dell’alterazione mitocondriale osservata è ancora in 
fase di studio. I risultati di questo lavoro mostrano comunque che anche la cascata del segnale di 
TGF-β converge al checkpoint mitocondriale regolando la distribuzione di trasduttori intracellulari 
a livello di domini funzionali critici e modulando l’uptake di Ca
2+ 
nella matrice mitocondriale e la 
sensibilità degli organelli a segnali di tipo proliferativo o apoptotico  
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INTRODUCTION 
Mitochondria: key regulators of intracellular calcium homeostasis 
Mitochondria are intracellular organelles characterized by a double membrane and a circular 
double-stranded DNA molecules. The double membrane is composed by a plain outer layer, which 
allows the passage of ions and metabolites up to 5000 Da and the more selective inner membrane, 
characterized by invaginations, the so called cristae. Between these two very different layers the 
mitochondrial matrix is enclosed. The mitochondrial DNA is a 16.6 Kb  molecule and it encodes 13 
proteins all of which are known to be part of the mitochondrial Electron Transport Chain (mETC). 
Thanks to their biosynthetic capacities mitochondria have central role in the supply of the high 
amount of energy required for many different cellular functions such as hormones synthesis and 
secretion, muscle contraction, proliferation, biomolecules synthesis and maintenance of ionic 
gradient across the membrane. Substrates derived from other intracellular processes such as 
glycolysis or the fatty acid metabolism, are converted to Acetyl-CoA which enters the Tricarboxilic 
Acid Cycle TCA and its complete degradation is coupled with the production of NADH and FADH2. 
These new molecules are the effective electron donors for the mETC which is composed of five 
different complexes: complex I (NADH dehydrogenase), complex II (succinate dehydrogenase), 
complex III (ubiquinol cytochrome c reductase), complex IV (cytochrome c oxidase) and complex V 
that constitutes the F1F0-ATP synthase. While electrons are transferred from NADH and FADH2 to 
these complexes, energy is stored as an electrochemical gradient across the inner membrane 
which explains the existence of a negative mitochondrial membrane potential (-180mV against the 
cytosol). The F1F0-ATP synthase can make the H
+
 cross the inner membrane to reenter the matrix 
coupling the energy derived from the proton gradient with the phosphorylation of ADP into ATP 
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(according to the so called chemiosmotic principle). The new ATP molecules are now ready to 
leave the mitochondria first from the inner membrane through the Adenine Nucleotide 
Transferase  (ANT) which exchanges it with ADP (to provide new substrate for the F1F0-ATP 
synthase) and then through a mitochondrial channel of the outer membrane called VDAC.  
In the last few decades many different groups are engaged in the comprehension of new roles for 
mitochondria which have shown to be involved in other cellular mechanisms such as amino-acid 
synthesis, lipid metabolism, reactive oxygen species production (ROS), cell death and, most 
importantly for the present work, Ca
2+
 signaling. Therefore any mitochondrial dysfunction is at the 
basis  of pathological conditions like neurodegenerative diseases such as Alzheimer’s and 
Parkinson’s, motoneuron disorders such as amyotrophic lateral sclerosis, autosomal dominant 
optic atrophy, diabetes, ageing and cancer. Thus it is evident how much importance has the 
understanding of the role of mitochondria in the cohordination of cytosolic and other subcellular 
organelles signals. 
 
Calcium signaling: a general overview 
Ca
2+
 is one of the most described intracellular second messenger (Hajnoczky G., 2000) and this is 
the reason why its cytosolic concentration [Ca
2+
]c is taken under strict control by many different 
pumps, channels, exchangers and binding proteins. Actually [Ca
2+
]c is maintained around value of 
100nM (while the extracellular [Ca
2+
] is 1mM) by the activity of the Plasma membrane Ca
2+
-ATPase 
(PMCA) which pump Ca
2+
 outside the cells and of the Na
+
/Ca
2+
 exchanger (NCX). The increased of 
the intracellular [Ca
2+
] is mainly due to its liberation from intracellular stores (Endoplasmic 
Reticulum and Golgi apparatus) or the entry from the extracellular medium. 
The most important intracellular Ca
2+ 
store is the ER which is characterized by the presence on his 
membrane of the IP3 Receptor (IP3R) a channel which exposes the binding site for IP3 on the 
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cytosol and forms a transmembrane channel across the ER membrane. Ca
2+ 
is released from the ER 
upon IP3R stimulation by IP3 that derives from the hydrolysis of phosphatidylinositol 4,5 
bisphosphate (PIP2) carried out by Phospholipase C (PLC) which, in its turn, is activated by ligand 
binding to G-coupled receptors on the plasma membrane. Intracellular store depletion activates 
an inward current from the extracellular space, the so called capacitative Ca
2+ 
entry (CCE) which 
molecular mechanism has been recently explained, with the involvment of an ER Ca
2+ 
sensing 
protein (STIM) and a Ca
2+ 
channel on the plasma membrane ORA1 (Oh-hora M. and Rao A., 2008).  
Three classes of Ca
2+ 
channel on the plasma membrane are also responsible of intracellular Ca
2+ 
increased: the Voltage Operated Ca
2+
 channels (VOCs) which open following a decrease of 
membrane potential (Bertolino M. and Llinas R.R., 1992), the Receptor Operated Ca
2+
 channels 
(ROCs), also called ligand gated channels, which open following the binding of an external ligand 
(McFadzean I. and Gibson A., 2002) and the Second Messenger Operated Channels (SMOCs) which 
open following the binding of a second messenger on the inner surface of the membrane 
(Meldolesi J. and Pozzan T., 1987). Ca
2+
 has to be rapidly removed once it has exerted its second 
messenger function and mechanisms for its extrusion are PMCA and NCX but also pumps capable 
to refill the intracellular stores such as Sarco-Endoplasmic Reticlum Ca
2+ 
ATPases (SERCAs). 
Mitochondria can rapidly accumulate Ca
2+ 
thanks to the electrochemical gradient established by 
the movement of protons across the inner mitochondrial membrane (IMM), however the 
development of specific probes for the measurement of [Ca
2+
]  in the mitochondria revealed a 
capacity of uptaking the ion much higher if compared with the affinity of [Ca
2+
] transporter, this is 
the reason why today it is generally accepted the idea of a strategic close proximity of a 
mitochondrial fraction able to sense short but large [Ca
2+
].    
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Mitochondria cohordinate Ca
2+ 
signaling 
By the end of 70’s mitochondria were thought to be intracellular Ca
2+ 
stores, indeed according to 
the chemosmotic theory these organelles could exploit the H
+
 electrochemical gradient to produce 
ATP but also to accumulate cations into the matrix. Ca
2+ 
transfer across the ion-impermeable 
membrane is in fact not due to the activity of pumps or exchangers but it is mediated by a 
“uniporter” which molecular identity has not been completely described yet and the 
electrochemical potential gradient across the mitochondrial membrane (-180mV negative to the 
cytosol) drives it (Gunter T.E., 1998). Moreover if Ca
2+  
accumulation into the matrix was due to 
thermodynamic parameters, according to the Nerst equation, equilibrium would be reached only 
when [Ca
2+
]  in the matrix reaches value 10
6 
higher than in the cytosol. 
Only a decade later, researchers discovered that the [Ca
2+
]m was lower than expected, this notion 
and the discovery of a new intracellular organelle the Endoplamic Reticulum (Streb H., 1983) made 
evident that mitochondria were not a Ca
2+ 
store. 
At the end of the 80s the general idea was that mitochondria could not accumulate significant 
amount of the cations considering the low affinity of their uniporter and the low values of the 
[Ca
2+
]c ,around 0.1 μM in normal conditions and 1-3 μM under stimulation. 
Nevertheless three mitochondrial enzymes (pyruvate-, α-ketoglutarate and isocitrate 
dehydrogenase) were regulated by Ca
2+ 
oscillations but the demonstration of this idea had to wait 
until the early 90s. Indeed the direct measurement of Ca
2+
  transients within the mitochondrial 
compartment was possible only in 1990s, when Rizzuto and coworkers introduced  the Ca
2+
-
sensitive probe aequorin, which could be targeted to mitochondria and other intracellular 
organelles.  These studies demonstrates in many different cellular type that the mitochondrial 
ability of uptaking Ca
2+
 was much more higher than expected (ranging from 10μM to 500μM). 
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Taking into consideration the low affinity of mitochondrial uniporter and the low concentration of  
Ca
2+ 
in the cytosol. This discrepancy lead the researchers to the formulation of the “hotspot 
hypothesis” according to which mitochondria could sense microdomains of high [Ca
2+
]   achieved 
through close proximity between a fraction of mitochondria and the ER. 
The release of Ca
2+ 
from the latter happens through the IP3 channels on its surface and this creates 
a microenviroments where [Ca
2+
]  is much higher than that measured in the bulk cytosol (Rizzuto 
R., 1993). Few years later a strong evidence in support of the “hotspot hypothesis” was that 
collected by Griffiths and coworkers, who observed that in cardiac cells concentrations of Ca
2+ 
chelator EGTA that could abolish Ca
2+ 
cytosolic transient, could not inhibit Ca
2+ 
transient into the 
mitochondria, this experiment suggested that the distance was so small that the cations could 
diffuse from ER to mitochondria more rapidly than it can be buffered by EGTA. 
The idea of a cross-talk between the two organelles was recently demonstrated by fast single-cell 
imaging with targeted Ca
2+ 
sensitive GFPs (pericams and cameleons) and supported by the 
observation that [Ca
2+
]m spikes originates from a discrete number of sites and rapidly diffuse 
through the mitochondrial network (Szabadkai G., 2004). 
Endoplasmic Reticulum/mitochondria physical contacts: the MAMs microdomains 
The existence of a subdomain of the ER (Endoplasmic Reticulum) that comes into transient contact 
with mitochondrial outer membranes, has been deeply demonstrated in mammalian cells and 
described as a functional site of the import of PS (Phosphatidylserine) into mitochondria (Vance 
JE., 2008). 
Close appositions between ER and mitochondria have been observed thanks to the analysis of 
electron micrographs (EM) in fixed samples of many different cell types while experiments 
performed in living cells by Rizzuto and coworkers had eventually confirmed the physical and 
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functional coupling of these two organelles, by labelling the two organelles with targeted spectral 
variants of GFP (mtBFP and erGFP) (Rizzuto R., 1998). These experiments revealed the presence of 
overlapping regions of the two organelles (thus establishing an upper limit of 100 nm for their 
distance) and allowed to estimate the area of the contact sites as 5-20% of total mitochondrial 
surface. More recently, electron tomography studies allowed to estimate an even smaller distance 
(10-25 nm) and revealed the presence of trypsin-sensitive (hence proteinaceous) tethers between 
the two membrane (Csordas A., 2006). 
The specific mitochondrial regions showing close proximity to the ER cisternae are referred to as 
MAMs (Mitochondrial Associated Membranes) (Vance JE., 1990) and being the headquarters of 
lipid transfer contain several phospholipids and glycosphingolipid-synthesizing enzymes such as 
Fatty Acid CoA ligase 4 (FACL) as well as those enzymes involved in PS synthesis pathway. 
MAMs are also involved in rapid movement of Ca
2+ 
ions between the two organelles, playing a 
fundamental role in the coordination of ATP production through the activation of the 
mitochondrial dehydrogenases as well as the activation of the cell death program (Berridge M. J., 
2002) . 
The shaping of the ER-mitochondrial network can be affected by bounding proteins and 
physiological ligands; recently Hajnoczky and coworkers demonstrated that exposure to TGFβ 
affects Ca
2+  
transfer to the mitochondria.(Hajnoczky G., 2008). 
Unfortunately, very few of the relevant scaffolding or signaling proteins of the ER/mitochondria 
contacts have been identified, despite the growing interest on the topic. Nevertheless, novel 
candidates have being rapidly isolated, and are under scrutiny. Thus it can be envisaged that the 
molecular characterization will rapidly proceed thanks to the validation of biochemical approaches 
for the isolation of ER/mitochondria contacts.  
  
11 
Indeed a known technical pitfall of subcellular fractionation, i.e. the “contamination” of the 
mitochondrial fraction with ER vesicles, has been demonstrated to be due to the actual co-
segregation of stably associated mitochondrial and ER membranes. This has led to a more accurate 
separation, by gradient centrifugations, of pure mitochondria from a “mitochondria-associated 
membrane” (MAM). This is the fraction enriched in enzymes involved in lipid and glucose 
metabolism and in signalling proteins (such as the IP3Rs), and thus representing the biochemical 
counterpart of the ER/mitochondria units revealed in the signaling studies (Vance J.E., 1990). More 
recently, the same subcellular fraction has been shown to contain as well Ca
2+
 signaling elements 
of both organelles (Szabadkai G., 2007), thus supporting its central role in ER (or SR)/mitochondria 
crosstalk .  
The molecular scenario is gradually adding new information, and we will here cite a couple of 
interesting examples, involving chaperones. The role of glucose-regulated protein 75 (grp75) 
within the mitochondrial matrix as a molecular chaperone assisting the refolding of newly 
imported proteins, was well established. It was then reported that a pool of grp75 is not imported 
into the matrix, but has a cytosolic distribution. Previous works carried out in our lab identified, in 
two hybrid screenings, grp75 as a VDAC interactor, and demonstrated that it can mediate the 
molecular interaction of VDAC with the IP3R, allowing a positive regulation of mitochondrial Ca
2+
 
uptake. This implies a sort of conformational coupling between the Ca
2+
 channels of the two 
organelles, and highlights the importance of macromolecular complexes located in the MAM for 
this functional interaction (Colombini M., 2004). The second interesting example is that of sigma-1, 
a novel ER chaperone serendipitously identified in cellular distribution studies which shown to be 
involved in the Ca
2+
-mediated stabilization of IP3Rs. Sigma-1 receptor is normally localized in 
MAM, bound to another ER chaperone (BiP). When the luminal Ca
2+
 concentration of the ER 
drops, following the opening of IP3Rs, sigma-1 dissociates from BiP and binds to type 3 IP3R, thus 
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preventing its degradation by the proteasome. Thus, sigma-1 appears to be involved in 
maintaining, from the ER luminal side, the integrity of the ER/mitochondrial Ca
2+
 cross-talk in 
conditions (e.g. ER stress) that could impair signal transmission, and hence control of cellular 
bioenergetics.  In 2005, Simmen et al. reported the identification of a multifunctional sorting 
protein PACS-2, that integrates ER-mitochondria and apoptosis signaling, depletion of this protein 
causes mitochondrial fragmentation and uncoupling from ER, influencing Ca
2+  
homeostasis. 
Moreover in response of apoptotic stimuli, PACS-2 has been demonstrated capable of inducing Bid 
recruitment to mitochondria, event that leads to cytochrome c release and caspase 3 activation.  
The dynamical interconnection between the two organelles involves a family of “mitochondria-
shaping proteins” such as the dynamin-related GTPase DRP1, required for the mitocondria-ER 
fission, or the GTPase called Optic Atrophy 1 (OPA 1) crucial for the so called mitofusion. Along this 
line, Scorrano and coworkers have recently pointed out the crucial role of the mitofusin (MFN 1 
and 2), in particular the isophorm 2 is thought to be important for ER-mitochondrial interactions 
engaging them both in homo and etero-complexes. (Scorrano L., 2008). They showed how the 
distance of two organelles is increased where MFN 2 lacks and how it impairs mitochondrial  Ca
2+ 
uptake, giving solid evidence in support to the microdomains theory. Moreover the ER-
mitochondrial apposition performed by MFN 2 predispose mitochondria to high  Ca
2+ 
microdomains and the consequent overloading, leading eventually to apoptosis by excessive Ca
2+ 
transfer.
  
 
Integration of the TGF-B pathway into the cellular signaling network 
Transforming growth factor–β (TGF-β) is a secreted cytochine that exerts an amazing diversity of 
biological effects including proliferation, differentiation, migration and apoptosis. The superfamily 
of TGF-β proteins comprises more than thirty members, the most important being TGF-β itself, 
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bone morphogenetic proteins (BMPs), activins and differentiation growth factors (GDFs). 
(Massaguè J. 1998). 
Considering the limited assortment of transmembrane receptors and downstream signaling 
molecules, the pivotal nature of TGF-β asks for a great flexibility of the signaling cascade, this is 
achieved thanks to  a complex network of mechanisms that control the activation of TGF-β in the 
extracellular space to modulate transcriptional activation in the nucleus. 
The variability of this pathway is generated by cell and tissue-specific composition, interaction of 
receptors, signal transducers, DNA-binding partners and finally the cross-talk with regulators from 
other pathways. 
TGF-β signal transduction: the basics 
Three human isoforms of TGF-β (TGF-β1, TGF-β2, TGF-β3) are synthesized as  large precursor 
which is processed to obtain the mature protein. Bioactive TGF-β homodimers signal through 
transmembrane serine/threonine  kinase receptors designated as TGF-β Receptor type I (TBRI) and 
type II (TβRII) (Frazen P. 1993). Initial binding to the constitutively active TβRII is followed by 
recruitment of TβRI into a heteromeric complex. Subsequent transphosphorylation of TβRI at the 
serine rich region, the so called GS-box, is mediated by TβRII and leads to activaton of TβRI. 
Interestingly TβRI  activation is not due to an increase of actual kinase activity but is rather based 
on the creation of a binding site for Smad proteins which represent the substrates for TβRI (Huse 
M. 2001). A key determinant  of TβRI-Smad interaction is represented by a region located in the 
kinase domain of TβRI called L45-loop. Within the L45-loop four amino acids that differ in TGF-β  
and BMP type I receptors, confer specificity for distinct Smad isoform and thus separate TGF-β and 
BMP pathways (Persson U. 1998). 
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Smad proteins can be divided into three subfamilies: receptor-activated Smads (R-Smads) 
including BMP-activated Smads (smad1, Smad5 and Smad8) and TGF-β activated Smads (Smad2 
and Smad3), the common mediator Smad4 (Co-Smad) and finally the inhibitory Smad6 and Smad7 
(I-Smads) (Heldin C.-H. 1997). TβRI causes R-Smad phosphorylation at the C-terminal SSXS-motif 
which is conserved among all R-Smads thereby causing dissociation from the receptor and 
heteromeric complex formation with Smad4 (Massaguè J. 2000). Smad complexes translocate to 
the nucleus, assemble with specific DNA-binding co-factors and co-modulators to finally activate 
transcription. The choice of target genes is thereby determined by the composition of the 
transcriptional complex. 
The Transforming growth factor-β signaling receptors 
In mammals only five type II receptors and seven type I receptors have been identified for ligand 
belonging to the large TGF-β superfamily. They all are transmembrane receptors that contain an 
intracellular serine/threonine kinase domain. 
The most described signaling receptors for TGF-β are TGF-β type II receptors (TGF-βRII) and the 
TGF-β type I receptor (TGF-βRI). In addition, two other TGF-β binding proteins called betaglycan 
(or TGF-βRIII) and endoglin are frequenty involved in formation of receptor complexes and 
function predominantly in ligand presentation. However as shown in table 1, the repertoire of 
TGF-β receptors is supplemented by other receptors or splice variants of the receptors that are 
also capable of transducing signals in response to TGF-β. Thus, signal diversity may be generated 
by different receptor combinations.  
In addition to TGF-β RI , there are other type I receptors such as ALK1 and ALK2 that transmit 
signals evoked by TGF-β. Pathological relevance is reflected by the linkage of mutations in both the 
endoglin and the ALK1 gene to an autosomal dominant disorder named hereditary hemorrhagic 
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teleangiectasia (HHT). Moreover ALK1 plays an important role during vascular development. ALK2 
is similar to ALK1 because it binds TGF-β following interaction with TGF-β receptor II and an 
accessory receptor and conveys the signal via the BMP-Smads, Smad1 and Smad5 respectively (Lai 
Y.T., 2000). 
Referring to type II receptors, it has a splice variant, TβRII-B which contains an insertion of 25 
aminoacids in the extracellular part of the receptor and shows functional differences. An 
outstanding physiological relevance for TβRII-B expression is therefore predicted for tissue such as 
bone, in which TGF-β2 represents the major TGF-β isoform. 
The major TGF-β-binding molecule on most cell type is TβRIII also called betaglycan, it is a 
transmembrane proteoglycan that is able to bind all three TGF-β isoforms via two independent 
binding sites in the core protein. TβRIII exerts its function in presenting TGF-β2 to TGF-βRII which 
shows only low intrinsic affinity for TGF-β2. In contrast to the facilitation of ligand access to the 
receptors, the soluble secreted domain of TGF-βRIII has antagonistic effects through binding and 
sequestering the ligand. The short cytoplasmic domain is rich in serines and threonines which 
represents suitable sites for phosphorylation. Indeed a previous report describes that 
phosphorylation of the cytoplasmic domain by autophosphorylated TGF-βRII initiates the release 
of TGF-βRIII from the active signaling complex, consisting in TGF-βRI and II and the bound ligand. 
A receptor variant that cross-regulates pathways of different members of the TGF-β family is 
represented by BMP and activin membrane bound inhibitor, this inhibitor is a pseudoreceptor 
similar to type I receptor apart from the lacking cytoplasmic kinase domain. Its capacity to 
associate with various type I receptor prevents the formation of functional homodimeric  type I 
receptor complexes and thus causes abrogation of BMP as well as TGF-β and activin–mediated 
signaling. 
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In conclusion the repertoire of signaling receptors gives rise to multiple hetero-oligomeric 
receptor complexes and each of the involved receptor variants depicts a distinct expression 
pattern, ligand isoform specificity and ligand affinity, thus expanding signal diversity. 
Distribution of different receptors 
The overall distribution of the TGF-β receptors is functional to the formation of different 
oligomeric units. TβRI, TβRII, TβRIII have all been found as homo-oligomers already in the absence 
of  TGF-β (Henis Y.I., 1994), in addition heteromeric complexes consisting of TβRII, TβRIII could be 
detected  in absence and in presence of TGF-β. Based on their affinity for each other, a small but 
detectable proportion of TβRI-TβRII heteromeric receptor complexes exists in unstimulated cells. 
The fraction of these heteromeric complexes is significantly increased by ligand binding to TβRII 
which causes subsequent recruitment of TβRI. 
The resulting tetrameric complexes consist of two molecules each of TβRI and  TβRII and represent 
the actual signaling entity (Luo K., 1997). Homomeric receptor complexes are not sufficient to 
propagate TGF-β responses but are considered to be functionally important for regulating 
receptor kinase activity, as reported in the case of intermolecular autophosphorylation at multiple 
serine residues of TβRII (Luo K., 1996). 
The ligand binding to TGF-β receptor triggers not only signaling but also initiates internalization of 
both ligand and receptor, in fact in absence of TGF-β, receptors are constantly internalized and 
recycled back to the membrane. Various proteins have been identified as capable of regulating 
TGF-β signaling. The basal receptor activity is kept under tight control by immunophilin FKBP12 
(Wang T.1994), by binding the unphosphorylated GS-box of TβRI, FKBP12 stabilizes a conformation 
of TGF-βRI that is incapable of getting transphosphorylation by TGF-ΒR II thus preventing ligand-
independent signaling. Ligand binding to TGF-βRII however induces conformational changes that 
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lead to displacement of FKBP12 and subsequent TGF-βR I activation by TGF-βR II (Huse M., 2001). 
Smad Anchor for Receptor Activation SARA  has a binding domain for R-Smads and the C-terminal 
part which directly interacts with the activated TGF-ΒR I. The cooperative binding of SARA proteins 
enables the Smads phosphorylation by TGF-βR I which is followed by the dissociation of them from 
SARA and formation of heteromeric complex with Smad4.  
The Disabled-2 protein Dab2 (Hocevar B.A., 2001) facilitates TGF-β signaling by bridging the 
receptors complex to the Smad proteins thanks to its N-terminal phosphotyrosine binding site PTB 
that is likely to allow association to the MH2 domain of Smad2 and Smad3.  
The TβRI-Associated Protein-1 TRAP-1 associates with Smad4 attracting the co-Smads to the 
vicinity of receptors thus facilitating heteromeric complex formation between activated R-Smads 
and Smad4. 
Negative regulation of TGF-β signaling is achieved by the inhibitory Smad7 (Nakao A., 1997), 
serine/threonine kinase receptor-associated protein STRAP or the Smad ubiquitination regulatory 
factors Smurf1 and 2. Smad7 lacks the SSXS-motif and so it is not a substrate for TβRI but it stably 
interacts with the activated receptor thereby competing with other R-Smads. STRAP was described 
to interact with both TβRI and TβRII and stabilizes the binding between TβRI and Smad7. Smurf 
proteins are bridged to the receptor by Smad7 and the ubiquitination of Smad7 leads to 
subsequent proteasomal and lysosomal degradation of the complex containing Smad7 and the 
TβRs. 
Downstream effectors of TGF-β pathway: the Smad proteins 
Smad proteins are so far the only known substrate for TβRs capable of transmitting the signal 
directly from the receptors to the nuclear transcriptional machinery. 
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Members of Smad family can be subdivide on the basis of their structural and functional 
properties: i) receptor activated Smads (R-Smads: Smad1, Smad5 and Smad8 (BMP activated); 
Smad2 and Smad3 (TGF-β activated) that become phosphorylated by type I receptors, ii)  common 
mediator Smad (Co-Smad: Smad4) which oligomerizes with R-Smads and iii) the inhibitory Smads 
(I-Smads: Smad6 and Smads7) which antagonize TGF-β or BMP signals by competing with R-Smads 
for type I receptor activation (Massaguè J., 1998). 
The overall structure of R-Smads and Co-Smads comprises the highly conserved N-terminal Mad 
homology 1 domain, MH1, and the C-terminal Mad homology 2 domain, MH2, which form 
globular structures, I-Smads contain the conserved MH2 domain but show little similarity in the N-
terminal (Itoh S., 2000). Smad proteins have no intrinsic enzymatic activity and exert their role 
exclusively by protein-protein or DNA-protein interactions. The MH1 domain mediates 
autoinhibition by physically interacting with the MH2 domain, impeding its function in the absence 
of ligand, moreover the MH1 domain is necessary also for the ability to bind directly to DNA. The 
crystal structure of Smad proteins reveal that  MH1 domain contains the hairpin-loop which is 
responsible for binding the DNA helix (Shi Y., 1998). Protein-protein interactions with transcription 
factors such as ATF2, c-Jun, SP1 or TFE3 are also mediated by MH1. This is the domain containing 
the nuclear localization signal NLS, for instance phosphorylation of Smad3 causes conformational 
changes that exposes its NLS-like motif allowing interaction with importin-β and recognition by the 
nuclear import machinery.  Ligand-induced release of SARA unmasks the NLS motif and leads to 
Smad nuclear translocation by a mechanism independent of importin-β but requiring the MH2 
domain.  
The cytoplasmic localization of Smad4 is based on active nuclear export signal NES, its nuclear 
entry presupposes inactivation of NES which is achieved by hetero-oligomerization with R-Smads 
(Pierreux C.E., 2000). 
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Recent publications suggest that Smad1 and Smad2 upon ligand induced phosphorylation 
assemble to form a homotrimer which is stabilized by the MH2 domain of the neighbouring 
monomer, however formation of heterotrimer is energetically favoured over the homotrimer 
formation.   
TGF-β induced activation of TGF-βRI is followed by transient interaction between TGF-βRI and R-
Smads which are phosphorylated in the last two serine residues within the C-terminal SSXS-motif, 
consequently Smad proteins are released from their retention such as SARA, as well as TGF-βRI 
and the affinity for Smad4 is increased. Several lines of evidence show that Smads are the 
substrates also for the ERK subfamily of MAP kinases which are activated by the hepatocyte 
growth factors or epidermal growth factors. Nuclear accumulation of Smad2 was demonstrated to 
be affected by Ca
2+
-calmodulin-dependent protein kinase II which triggers phosphorylation of 
several serine residues of Smad proteins (Wicks S.J., 2000). Protein Kinase C activated by TGF-β, 
provides a negative feedback by phosphorylating specific serine residues in the MH1 domain of 
Smad3 thus precluding its ability to bind the DNA. Further cytoplasmic kinases mediating Smad 
phosphorylation is the c-Jun N-terminal kinase JNK. TGF-β stimulates JNK  and it leads to the 
phosphorylation of Smad3 at sites other than the SSXS motif, facilitating the following 
phosphorylation by TGF-βR I. 
Several proteins negatively regulate TGF-β signaling , first of all inhibitory Smads rapidly induced 
by TGF-β, block phosphorylation of Smads, second Smad binding proteins and transcriptional co-
repressors, third the Smurf proteins that target Smads for degradation, however the most obvious 
mechanism is the dephosphorylation of R-Smads after prolonged TGF-β stimulation.  
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TGF-β and Mitochondrial function 
A functional relationship between TGF-β signaling and mitochondria has already been established 
by many different groups, for instance in regulating the intrinsic pathway of apoptosis. Gottfried et 
al. demonstrated that ARTS, a proapoptotic protein localized in the mitochondria, is essential for 
TGF-β-induced programmed cell death (Gottfried Y., 2004). In epithelial cell it has been observed 
that TGF-β treatment causes generation of reactive oxygen species and the consequent loss of 
mitochondrial membrane potential (Δψ) which leads to activate the programmed cell death 
(Wang F., 2008). Clybouw et al. in 2008 showed that in early stages of tumor progression, TGF-β 
mediates apoptosis of epithelial and hepatocyte cells by leading Bim (a proapoptotic member of 
the BH3-only proteins) at the mitochondrial surface where it associates with Bcl-2 or Bcl-xL. The 
sequestration of these prosurvival members of the Bcl-2 family by Bim allows the activation of the 
apoptotic regulators Bax and Bak (Clybouw C., 2008). Moreover mutations in specific TGF-β family 
members proved to be linked to altered mitochondrial energy metabolism and oxygen 
consumption rate. (Liunan L., 2009). 
Recently a new potential role has been demonstrated for TGF-β in the impairment  of normal 
mobilization of intracellular Ca
2+
 stores (McGowan T.A., 2000), prior studies showed the reduction 
in IP3R1 Ca
2+ 
release in diabetic aortic and proglomerular smooth muscle cells which is indeed 
mediated by TGF-β (Sharma K., 2003). Thus the impairment of vascular cell dysfunction has been 
directly linked to the IP3 –cytoplasmic Ca
2+ 
signaling.  
A key aspect of endoplasmic reticulum (ER) Ca
2+ 
release is its
 
coupling with the mitochondria 
(Rizzuto R. and Pozzan T., 2006) and Ca
2+ 
mobilized through the IP3 receptors or ryanodine 
receptors is effectively transferred to the mitochondria and stimulates, in the mitochondrial 
matrix, the ATP production. 
  
21 
Mitochondrial Ca
2+ 
uptake exerts positive and negative feedback effects on the IP3 receptor- 
mediated ER Ca
2+ 
mobilization and affects SERCA pump-mediated ER Ca
2+
 reuptake. Moreover 
mitochondrial Ca
2+ 
uptake  regulates the mitochondrial phase of cell death, thus a well described 
binding between Ca
2+ 
overload in the mitochondrial matrix and the activation of the apoptotic 
process has been already understood. Since TGF-β has been implicated as a key factor in many 
cellular processes, many different groups have been doing great efforts to understand the 
mechanism by which TGF-β may affect ER-mitochondrial communication.  
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AIMS 
In the present study we observed a close relationship between the presence of the downstream 
effectors of TGF-β cascade in specific mitochondrial functional sites and the shaping of 
mitochondrial calcium homeostasis. Mitochondria can sense microdomains of high [Ca
2+
] thanks 
to their close proximity to the ER. Recent work has demonstrated that the subcellular fraction 
denominated Mitochondria-Associated Membranes (MAMs) may correspond to this signaling 
domain which happen to be enriched in Ca
2+
 channels and regulatory proteins. The Transforming 
growth factor-β is known to have crucial roles in the regulation of cell proliferation, differentiation 
and apoptosis. The downstream effectors of TGF-β signaling are intracellular proteins called Smads 
that hetero-oligomerize after phosphorylation and subsequently migrate into the nucleus to 
influence gene expression. While much progress has been made in understanding TGF-β 
regulation of gene expression, the subcellular distribution of Smad proteins and their nuclear-
independent activity are still incompletely understood. 
We have investigated the effect of the TGF-β signaling on intracellular Ca
2+
 homeostasis. The 
results showed that Smad2/3, both in HeLa cells and in liver preparations, are present in 
mitochondria, with a specific enrichment in the MAM fraction. Such a distribution may underlie a 
direct, transcription-independent role in the modulation of the ER/mitochondria Ca
2+
 cross-talk. 
This possibility has been directly investigated using aequorin-based recombinant probes targeted 
to the mitochondria, the ER and the cytosol. Specifically, we observed that treatment with 
inhibitors of the TGF-β receptor family, such as SB431542 and Dorsomorphin (Compound C) 
reduces agonist-dependent increases of mitochondrial Ca
2+
 concentration [Ca
2+
]m, while leaving 
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the cytosolic responses unaffected. The effects were observed also upon inhibition of protein 
synthesis, thus ruling out the possibility that they are due to alterations of the expression levels of 
Ca
2+
 transporters. The same effects were observed by shRNA silencing of Smads, thus involving 
these TGF-β transducers in the mitochondrial effects. Work is currently under way to identify the 
mechanism of the Ca
2+
 signalling alterations (intrinsic desensitization of the MCU, reduction of the 
electrochemical driving force, etc.). 
Altogether, these data demonstrate that also the TGF-β signaling pathway converges on 
mitochondrial checkpoint, clustering intracellular transducers in critical signaling domains and 
modulating Ca
2+
 loading and the sensitivity to growth-promoting and apoptotic challenges.  
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MATERIALS AND METHODS 
Aequorin:  a Ca
2+
 sensitive probe 
 
Aequorin is a 21 KDa protein isolated from jellyfish of the genus Aequorea which emits blue light 
in presence of calcium ions. The aequorin originally purified from jellyfish is a mixture of different 
isoforms called “heterogeneous aequorin” (Shimomura O., 1986). In its active form the 
photoprotein includes an apoprotein and a covalently bound prosthetic group, coelenterazine. 
When calcium ions bind to the three high affinity EF hand sites, coelenterazine is oxidized to 
coelenteramide, with a concomitant release of carbon dioxide and emission of light.  
Although this reaction is irreversible, in vitro an active aequorin can be obtained by incubating the 
apoprotein with coelenterazine in the presence of oxygen and 2-mercaptoethanol. Reconstitution 
of an active aequorin (expressed recombinantly) can be obtained also in living cells by simple 
addition of coelenterazine to the medium. Coelenterazine is highly hydrophobic and has been 
shown to permeate cell membranes of various cell types, ranging from the slime mold 
Dictyostelium discoideum to mammalian cells and plants. 
Different coelenterazine analogues have been synthesized that confer to the reconstituted protein 
specific luminescence properties (Shimomura O., 1993). A few synthetic analogues of 
coelenterazine are now commercially available from Molecular Probes. 
The possibility of using aequorin as a calcium indicator is based on the existence of a well 
characterized relationship between the rate of photon emission and the free Ca
2+
 concentration. 
For physiological conditions of pH, temperature and ionic strength, this relationship is more than 
quadratic in the range of [Ca
2+
] 10
-5
-10
-7
 M. The presence of 3 Ca
2+
 binding sites in aequorin is 
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responsible for the high degree of cooperativity, and thus for the steep relationship between 
photon emission rate and [Ca
2+
]. The [Ca
2+
] can be calculated from the formula L/Lmax, where L is 
the rate of photon emission at any instant during the experiment and Lmax is the maximal rate of 
photon emission at saturating [Ca
2+
]. The rate of aequorin luminescence is independent of [Ca
2+
] 
at very high (>10
-4
 M) and very low [Ca
2+
] (< 10
-7
 M). However, as described below in more details, 
it is possible to expand the range of [Ca
2+
] that can be monitored with aequorin. Although 
aequorin luminescence is not influenced either by K
+
 or Mg
2+
 (which are the most abundant 
cations in the intracellular environment and thus the most likely source of interference in 
physiological experiments) both ions are competitive inhibitors of Ca
2+
 activated luminescence. 
Aequorin photon emission can be also triggered by Sr
2+
 but its affinity is about 100 fold lower than 
that of Ca
2+
, while lanthanides have high affinity for the photoprotein (e.g. are a potential source 
of artifacts in experiments where they are used to block Ca
2+
 channels). pH was also shown to 
affect aequorin luminescence but at values below 7. Due to the characteristics described above, 
experiments with aequorin need to be done in well-controlled conditions of pH and ionic 
concentrations. 
Recombinant aequorins.  
 
For a long time the only reliable way of introducing aequorin into living cells has been that of 
microinjecting the purified protein. This procedure is time consuming and laborious and requires 
special care in handling of the purified photoprotein. Alternative approaches (scrape loading, 
reversible permeabilization, etc.) have been rather unsuccessful. The cloning of the aequorin gene 
has opened the way to recombinant expression and thus has largely expanded the applications of 
this tool for investigating Ca
2+
 handling in living cells. In particular, recombinant aequorin can be 
expressed not only in the cytoplasm, but also in specific cellular locations by including specific 
targeting sequencing in the engineered cDNAs. Extensive manipulations of the N-terminal of 
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aequorin have been shown not to alter the chemiluminescence properties of the photoprotein 
and its Ca
2+
 affinity. On the other hand, even marginal alterations of the C-terminal either abolish 
luminescence altogether or drastically increase Ca
2+
 independent photon emission. As 
demonstrated by Watkins and Campbell, the C-terminal proline residue of aequorin is essential for 
the long-term stability of the bound coelenterazine (Watkins N.J., and Campbell A.K., 1993). For 
these reasons, all targeted aequorins synthesized in our laboratory include modifications of the 
photoprotein in the N-terminal. Three targeting strategies have been adopted: 
1. Inclusion of a minimal targeting signal sequence to the photoprotein cDNA. This strategy was 
initially used to design the mitochondrial aequorin and was followed also to synthesize an 
aequorin localized in the nucleus and in the lumen of the Golgi apparatus. 
2. Fusion of the cDNA encoding aequorin to that of a resident protein of the compartments of 
interest. This approach has been used to engineer aequorins localized in the sarcoplasmic 
reticulum (SR), in the nucleoplasm and cytoplasm (shuttling between the two compartments 
depending on the concentration of steroid hormones), on the cytoplasmic surface of the 
endoplasmic reticulum (ER) and Golgi and in the subplasmalemma cytoplasmic rim. 
3. Addition to the aequorin cDNA of sequences encoding for polypeptides that bind to 
endogenous proteins. This strategy was adopted to localize aequorin in the ER lumen. We 
routinely included in all the recombinant aequorins the HA1 epitope-tag that facilitates the 
immunocytochemical localization of the recombinant protein in the cell. 
Chimeric aequorin cDNAs  
 
Below we briefly describe the constructs produced in our laboratory. A few other constructs have 
been produced in other laboratories and will not be dealt with in detail here. 
Cytoplasm (cytAEQ): an unmodified aequorin cDNA encodes a protein that, in mammalian cells is 
located in the cytoplasm and, given its small size, also diffuses into the nucleus. An alternative 
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construct is also available that is located on the outer surface of the ER and of the Golgi apparatus. 
This construct was intended to drive the localization of aequorin to the inner surface of the plasma 
membrane given that it derives from the fusion of the aequorin cDNA with that encoding a 
truncated metabotropic glutamate receptor (mgluR1). The encoded chimeric protein, however, 
remains trapped on the surface of the ER and Golgi apparatus, with the aequorin polypeptide 
facing the cytoplasmic surface of these organelles. The cytoplasmic signal revealed by this chimeric 
aequorin is indistinguishable from that of a cytoplasmic aequorin, but it has the advantage of 
being membrane bound and excluded from the nucleus. 
Mitochondria (mtAEQ): mtAEQ was the first targeted aequorin generated in the laboratory, which 
has been successfully employed to measure [Ca
2+
] of mitochondrial matrix of various cell types. 
This construct includes the targeting presequence of subunit VIII of human cytochrome c oxidase 
fused to the aequorin cDNA. 
Endoplasmic Reticulum (erAEQ):The erAEQ includes the leader (L), the VDJ and Ch1 domains of an 
Ig2b heavy chain fused at the N-terminal of aequorin. Retention in the ER depends on the 
presence of the Ch1 domain that is known to interact with high affinity with the luminal ER protein 
BiP. 
To expand the range of Ca
2+
 sensitivity that can be monitored with the different targeted 
aequorins we have also employed in many of our constructs a mutated form of the photoprotein 
(asp119 → ala). This point mutation affects specifically the second EF hand motive of wild type 
aequorin. The affinity for Ca
2+
 of this mutated aequorin is about 20 fold lower than that of the wild 
type photoprotein. Chimeric aequorins with the mutated isoform are presently available for the 
cytoplasm, the mitochondrial matrix, the ER and SR, the Golgi apparatus and the sub- 
plasmamembrane region. 
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Cell preparation and transfection 
Although in a few cases the aequorin cDNA has been microinjected, the most commonly employed 
method to obtain expression of the recombinant protein is transfection. Different expression 
plasmids have been employed, some commercially available (pMT2, pcDNAI and 3) other have 
been kindly provided by colleagues. The calcium phosphate procedure is by far the simplest and 
less expensive and it has been used successfully to transfect a number of cell lines, including HeLa, 
L929, L cells, Cos 7, A7r5 and PC12 cells, as well as primary cultures of neurons and skeletal muscle 
myotubes. Other transfection procedures have been also employed, such as liposomes, the “gene 
gun” and electroporation. Viral constructs for some aequorins are also available (Alonso M.T. 
1998; Rembold C.M., 1997). In this section we briefly describe the calcium phosphate procedure, a 
simple and convenient transfection method for HeLa cells. 
One day before the transfection step, HeLa cells mantained in Dulbecco Modified Eagle’s Medium 
(DMEM) supplemented with 10% Fetal Bovine serum (FBS) are plated on a 13 mm round coverslip 
at 30-50% confluence. Just before the transfection procedure, cells are washed with 1 ml of fresh 
medium. 
Calcium-Phosphate transfection procedure 
The following stock solutions need to be prepared and conserved at -20°C until used: CaCl2 2.5 M, 
HEPES Buffered Solution (HBS): NaCl 280mM, Hepes 50 mM, Na2HPO4 1.5 mM, pH 7.12, Tris-EDTA 
(TE): Trizma-base 10mM, EDTA 1mM, pH 8. 
All solutions are sterilized by filtration using 0.22 μm filters. For one coverslip, 5 μl of CaCl2 2.5 M 
are added to the DNA dissolved in 45 μl of TE. Routinely, 4 μg of DNA are used to transfect one 
coverslip. The solution is then mixed under vortex with 50 μl of HBS and incubated for 20 to 30 
minutes at room temperature. The cloudy solution is then added directly to the cell monolayer. 
18-24 hours after addition of the DNA, cells are washed with PBS (2 or 3 times until the excess 
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precipitate is completely removed). Using this protocol the transfected cells are usually between 
30 and 50 %. Although an optimal transfection is obtained after an overnight incubation, we found 
that a substantial aequorin expression, sufficient for most experimental conditions, is obtained 
also with an incubation of only 6 hours with the Ca
2+
-phosphate-DNA complex.  
Reconstitution of functional aequorin 
Once expressed, the recombinant aequorin must be reconstituted into the functional 
photoprotein. This is accomplished by incubating cells with the synthetic coelenterazine for 
variable periods of time (usually 1-3 hours) and under conditions of temperature and [Ca
2+
] that 
depend on the compartment investigated. Practically, coelenterazine is dissolved at 0.5 mM in 
pure methanol as a 100X stock solution kept at - 80°C. This solution tolerates several freeze-thaw 
cycles. 
However, we recommend the supply of coelenterazine solution to be split into small aliquots (50 
μl). Coelenterazine must be protected from light. 
For compartments with low [Ca
2+
] under resting conditions (cytosol and mitochondria) the cells 
transfected with the appropriate recombinant aequorins are simply incubated at 37°C in fresh 
DMEM medium supplemented with 1% FBS and 5 μM coelenterazine. Higher or lower 
coelenterazine concentrations can be also used, if necessary. Good reconstitution is achieved with 
1hour incubation, but an optimal reconstitution requires 2 hours. 
For compartments endowed with high [Ca
2+
] under resting conditions (ER), to obtain good 
reconstitution and interpretable data it is first necessary to reduce the [Ca
2+
] in the organelle, 
otherwise aequorin would be immediately consumed after reconstitution and in steady state little 
functional photoprotein would be present in cells. Depletion of Ca
2+
 from the organelles can be 
achieved in different ways. Here we describe a simple protocols: cells are incubated at 37°C for 5 
minutes in KRB solution (Krebs-Ringer modified buffer: 125 mM NaCl, 5mM KCl, 1mM Na3PO4, 
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1mM MgSO4, 5.5 mM glucose, 20 mM Hepes, pH 7.4) supplemented with 600 μM EGTA, 10 μM 
ionomycin). After washing with KRB containing 100 μM EGTA and 5% bovine serum albumin, cells 
are further incubated in the same medium supplemented with 5 μM coelenterazine for 1 hour, 
but at 4°C. 
Slight variations in these depletion protocols have been used both by our group and other 
investigators. Here it is necessary to stress a few general aspect of the procedure: i) the more 
efficient the Ca
2+
 depletion, the better the reconstitution; ii) some compartments (e.g. the Golgi 
and in part the ER) can deeply morphologically altered by the Ca
2+
 depletion protocol. The 
incubation at 4°C largely prevents these morphological changes, without altering the efficacy of 
the reconstitution; iii) if ionophores or SERCA inhibitors are employed for depletion they must be 
removed completely before starting the experiment. For this reason extensive washing of the cell 
monolayer with Bovine Serum Albumin (BSA) is recommended at the end of the reconstitution 
procedure. 
Luminescence detection 
 
The aequorin detection system is derived from that described by Cobbold and Lee and is based on 
the use of a low noise photomultiplier placed in close proximity (2-3 mm) of aequorin expressing 
cells. The cell chamber, which is on the top of a hollow cylinder, is adapted to fit 13-mm diameter 
coverslip. The volume of the perfusing chamber is kept to a minimum (about 200 μl). The chamber 
is sealed on the top with a coverslip, held in place with a thin layer of silicon. Cells are continuosly 
perfused via a peristaltic pump with medium thermostated via a water jacket at 37°C. The 
photomultiplier (EMI 9789 with amplifier-discriminator) is kept in a dark box and cooled at 4°C. 
During manipulations on the cell chamber, the photomultiplier is protected from light by a shutter. 
During aequorin experiments, the shutter is opened and the chamber with cells is placed in close 
proximity of the photomultiplier. The output of the amplifier-discriminator is captured by an 
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EMIC600 photon-counting board in an IBM compatible microcomputer and stored for further 
analysis. 
Ca2+ measurement 
For the cells transfected with cytosolic, mitochondria or nuclear aequorins, the coverslip with the 
transfected cells is transferred to the luminometer chamber and it is perfused with KRB saline 
solution in presence of 1 mM CaCl2 to remove the excess coelenterazine. The stimuli or drugs to 
test are added to the perfusing medium and reach the cells with a lag time that depends on the 
rate of the flux and the length of the tubes. In order to make the stimulation more rapid and 
homogeneous the rate of the peristaltic pump is set to its maximum speed. Under these 
conditions we calculated that the whole monolayer is homogeneously exposed to the stimuli in 2 
sec. At the end of the experiments, all the aequorin is discharged by permeabilizing the cells using 
a hypotonic solution containing digitonin (100 μM) and CaCl2 (10 mM). 
For erAEQ transfected cells, unreacted coelenterazine and drugs are removed by prolonged 
perfusion (3-6 min) with a saline solution containing 600 μM EGTA and 2% BSA. BSA is then 
removed from the perfusion buffer and the refilling of the compartments is started by perfusing 
the medium containing 1mM CaCl2. To note that BSA increases luminescence background level. 
We found that, despite the depletion protocol and the use of a low Ca
2+
 affinity aequorin mutant, 
the rate of aequorin consumption upon Ca
2+
 refilling is so rapid that most aequorin is consumed in 
30 sec and the calibration of the signal in terms of [Ca
2+
] becomes unreliable. Two alternative 
solutions to this problem have been developed, i) the use of Sr
2+
 as a Ca
2+
 surrogate and ii) the 
reconstitution not with the wild type coelenterazine, but with the analogue coelenterazine n that 
reduces the rate of aequorin photon emission at high [Ca
2+
]. In the latter case [Ca
2+
] between 10
-4
 
and 10
-3
 M can be reliably calibrated (Robert V., 1998). 
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Conversion of the luminescent signal into [Ca2+] 
To transform luminescence values into [Ca
2+
] values, we have used the method described by Allen 
and Blink. The method relies on the relationship between [Ca
2+
] and the ratio between the light 
intensity recorded in physiological conditions (L, counts/s) and that which would have been 
reported if all the aequorin was instantaneously exposed to saturating [Ca
2+
] (Lmax). Given that the 
constant rate of aequorin consumption at saturating [Ca
2+
] is 1.0 s
-1
, a good estimate of Lmax can be 
obtained from the total aequorin light output recorded from the cells after discharging all the 
aequorin. This usually requires the addition of excess Ca
2+
 and detergents as shown in the previous 
section. As aequorin is being consumed continuously, it must be stressed that, for calibration 
purposes, the value of Lmax is not constant and decreases steadily during the experiment. The value 
of Lmax to be used for [Ca
2+
] calculations at every time point along the experiment should be 
calculated as the total light output of the whole experiment minus the light output recorded 
before that point. 
The relationship between the ratio (L/Lmax) and [Ca
2+
] has been modeled mathematically. 
The model postulates that each of the Ca
2+
 binding sites has two possible states, T and R and that 
light is emitted when all the sites are in the R state. Ca
2+
 is assumed to bind only in the R state. 
This model contains three parameters: KR, the Ca
2+
 association constant, KTR= [T]/[R], and n, the 
number of Ca
2+
 binding sites. The values we obtained for the recombinantly expressed aequorin 
for each parameter are: KR = 7.23 10
6
 M
-1
, KTR = 120, n=3. The equation for the model provides 
the algorithm we used to calculate the [Ca
2+
] values at each point where Ratio is (L/Lmax)1/n. 
Ca
2+
(M) = Ratio + (Ratio x KTR)-1 
                 KR – (Ratio x KR) 
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Imaging techniques 
All imaging experiments were carried out on Zeiss Axiovert 200 inverted microscopes, equipped 
with cooled CCD digital cameras. Z-series of images were acquired at 0.5 μm distance, 
deconvolved using a custom-made algorithm and 3D reconstructed as described previously 
(Carrington W.A., 1995; Rizzuto R., 1998b). 
 
ATP  measurements 
Luciferase assay was carried out, as previously described. (Jouaville L. S. 1999). In brief, HeLa cells 
(50,000-70,000 per coverslip) were transfected with mitochondrial targeted luciferase (mtLUC)  
according to a standard calcium-phosphate procedure. 
24 hours after transfection, the coverslip with the cells was transferred to the 37°C termostated 
chamber of a luminometer and perfused with a Krebs Ringer Buffer containing: 125mM NaCl, 
5mM KCl, 1mM Na3PO4, 1mM MgSO4, 20μM Luciferin, 20mM Hepes, 5,5 mM Glucose (pH7,4). 
Luminescence is entirely dependent on the continuosly provided luciferin and proportional to its 
concentration between 20 and 200 μM. After a preliminary phase of equilibration, during which 
light emission of  mitochondrial luciferase transfected cells was in the range of 14000-16000 cps 
versus a background lower than 10 cps, cellular response was evoked by the agonist Histamine 
100μM added to the perfusion medium. 
 
Subcellular fractionation and proteomic analysis 
HeLa cells and mouse liver were homogenized, and crude mitochondrial fraction (8,000g pellet) 
was obtained. Mouse tissue was subjected to separation on a 30% self-generated Percoll gradient 
as described previously (Vance J.E., 1990). A low-density band (denoted as MAM fraction) was 
collected and analysed by immunoblotting. For SDS-PAGE analysis of MAM fraction proteins 10 μg 
proteins were loaded on 10% SDS-polyacrilamyde gels. The antibodies used were: αIP3R3, isotype 
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specific monoclonal antibody, 1:1000, Cell Signaling; αVDAC2, 1:1000 Molecular Probe; Smad2/3 
monoclonal antibody 1:1000, Cell Signaling, phospho-Smad3 1:1000 monoclonal antibody, Cell 
Signaling; αActin 1:10000 Cell Signaling;  Sigma Receptor 1, 1:1000 monoclonal antibody, Sigma. 
 
The pSUPER RNAi system 
 
In several organisms, introduction of double-stranded RNA has proven to be a powerful tool to 
suppress gene expression through a process known as RNA interference. However, in most 
mammalian cells this provokes a strong cytotoxic response. This non-specific effect can be 
circumvented by use of synthetic short [21- to 22-nucleotide] interfering RNAs (siRNAs), which 
can mediate strong and specific suppression of gene expression. However, this reduction in gene 
expression is transient, which severely restricts its applications. To overcome this limitation, the 
pSUPER RNAi system provides a mammalian expression vector that directs intracellular synthesis 
of siRNA-like transcripts. The vector uses the polymerase-III H1-RNA gene promoter, as it produces 
a small RNA transcript lacking a polyadenosine tail and has a well-defined start of transcription 
and a termination signal consisting of five thymidines in a row (T5). Most important, the cleavage 
of the transcript at the termination site is after the second uridine, yielding a transcript resembling 
the ends of synthetic siRNAs, which also contain two 3’ overhanging T or U nucleotides. The 
pSUPER RNAi System has been used to cause efficient and specific down-regulation of gene 
expression, resulting in functional inactivation of the targeted genes. Stable expression of siRNAs 
using this vector mediates persistent suppression of gene expression, allowing the analysis of loss-
of-function phenotypes that develop over longer periods of time. To effect the silencing of a 
specific gene, the pSUPER vector is used in concert with a pair of custom oligonucleotides that 
contain, among other features, a unique 19-nt sequence derived from the mRNA transcript of the 
gene targeted for suppression (the “N-19 target sequence”). 
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The N-19 target sequence corresponds to the sense strand of the pSUPER-generated siRNA, which 
in turn corresponds to a 19-nt sequence within the mRNA. In the mechanism of RNAi, the 
antisense strand of the siRNA duplex hybridizes to this region of the mRNA to mediate cleavage of 
the molecule. The technical procedure is summarized in the following paragraph. 
 
>> Step One: Anneal Oligos 
Two custom DNA oligonucleotides were dissolved in sterile, nuclease-free H2O to a concentration 
of 3 mg/ml. The annealing reaction was assembled by mixing 1 μl of each oligo (forward and 
reverse) with 48 μl annealing buffer (100 mM NaCl and 50 mM HEPES pH 7.4) and incubated at 
90°C for 4 minutes, and then at 70°C for 10 minutes. Slowly the annealed oligos were cooled to 
10°C. 
>> Step Two: Linearize the Vector  
1 μl of the pSUPER vector was linearized with Bgl II and Hind III restriction enzymes, then the 
reaction was heat inactivated (raising the temperature to 65 or 80°C for 20 minutes). Following 
digestion, purification of the linearized vector, on a 1% agarose gel, was performed to remove the 
fragment, and to help to separate the prep from any undigested circular plasmid and to decrease 
the background in ligation and transformation. 
>> Step Three: Ligation into pSUPER Vector 
For the ligation 2 μl of the annealed oligos, 1μl of T4 DNA ligase buffer, 1μl pSUPER vector, 5μl 
nuclease-free H2O, and 1μl T4 DNA ligase were assembled and incubated overnight at room 
temperature. A negative control cloning reaction was performed with the linearized vector alone 
and no insert. 
>>Step Four: Transformation in Bacteria 
Recombinant pSUPER vector was transformed into competent cells. In order to monitor the 
efficiency of the transformation steps, as a negative control, cells should also be transformed 
either with a vector that has been ligated with a scrambled-base hairpin oligo, or with a circular 
vector containing no oligo insert. Bacteria were grown in amp-agarose plates overnight (16-24 
hrs), then colonies were chosen for additional cycle in an ampicilin broth. Finally we checked the 
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presence of positive clones by digesting with EcoRI and Hind III. After digestion, we determine our 
results as follows: 
Positive clone: vector with insert of 281 bp  
Negative clone: vector with insert of 227 bp  
In addition, the presence of the correct insert within recombinant pSUPER vector was confirmed 
by sequencing prior to transfection in mammalian cells.  
 
High-throughput assay based on  a SiRNAs Library  
 
A custom siRNA library targeting 750 human kinases with three fold redundancy was obtained 
from Ambion Inc. and the three siRNA duplexes for  each target were individually arrayed in 96-
well format. A stable clone of HeLa cells overexpressing mitochondrial targeted aequorin probe 
was exploited. Cells were seeded on 96-well plates at density of 10000 cells per well and cultured 
overnight at 37°C. 24 hours post-seeding cells were transfected with 50nM siRNA using 
Lipofectamine 2000 reagent. Forty-eight hours after transfection, thanks to the MicroBeta 
multiplate reader, cells were challenged with histamine 50μM and mitochondrial calcium 
transients were measured. 
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RESULTS 
High throughput screen of human kinases for the identification of new regulators of 
mitochondrial calcium signaling 
To establish the role of protein kinases in mitochondrial calcium signaling we designed a functional 
assay  based on RNA interference to perform a genetic screen using small interfering RNA (siRNA) 
targeting the complete array of human kinases.  HeLa cells were systematically co-transfected with 
the mitochondrially targeted probe aequorin and siRNAs using a kinome library comprising 750 
kinases at three fold redundancy. 48 hours post transfection HeLa cells were measured by the 
multi detector system MicroBeta JET based on the biolumiscent reaction of Aequorin. The 
aequorin photoprotein undergoes a bioluminescent reaction in the presence of calcium ions, 
producing a flash of light at 469 nm. This wavelength correlates well with the maximum efficiency 
of the photo-multiplier tubes used in the MicroBeta. 
aequorin + Ca
2+
 –> apoaequorin + coelenteramide + CO2 + light (469nm) 
 
The effect of each siRNA was compared with that of a validate one (VDAC2 siRNA) and that of a 
scrambled sequence, both of them were transfected on each single plate and measured along with 
the respective samples. 
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Figure 1 
  
Fig. 1 MicroBeta® JET is a multi-detector instrument designed for liquid scintillation or luminescence detection of 
samples in microplates, tubes or on filters. MicroBeta JET also includes one or more reagent injectors for measuring 
prompt (or ‘flash’) reactions. Multi-detector versions of the instrument can have one or two Injector Modules installed 
to measure one or two injection and counting sequences. 
The single detector MicroBeta JET can have up to four Injector Modules. 
 
 
Calcium transients were measured  in HeLa cells, after reconstitution with the aequorin co-factor 
coelenterazine, cells were challenged with histamine 100 μM and luminescence was measured 
and converted in numbers representing the percentage of probe consumption after agonist 
stimulation, this number was transformed in a percentage of variation of each sample compared 
to the scrambled siRNA spotted on each plate and Library samples are shown in Table1.  Table 1 
contains  proteins which the three siRNA sequences exert the same effect on mitochondrial 
calcium uptake, 217 kinases, (28.9% of the entire array) among them the 4.1% shows an increasing 
in calcium uptake more than 20% while the 37.8%  reduces it more than 20% (Fig.2). For 186 
(24.8%) human kinases only two siRNA sequences out of three showed consistent effects on 
mitochondrial calcium signaling, the third one producing no effect at all. The last subgroup of 347 
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(46.26%) kinases consisted in those with no reproducible effect on calcium transients (data not 
shown).    
 
Table1 
Plate_N° Row Col Symbol % varsiRNA/scrambled full_name locus_link_id 
17 B 4 TLK1 -50.7 tousled-like kinase 1 9874 
11 C 2 EPHB2 -48.0 EphB2 2048 
11 C 1 EPHB1 -43.0 EphB1 2047 
11 C 10 FGFR1 -42.4 
fibroblast growth factor 
receptor 1 (fms-related 
tyrosine kinase 2, Pfeiffer 
syndrome) 2260 
11 B 1 DDR1 -40.5 
discoidin domain receptor 
family, member 1 780 
11 H 3 TXK -40.2 TXK tyrosine kinase 7294 
11 B 9 EPHA5 -39.7 EphA5 2044 
11 C 4 EPHB4 -39.6 EphB4 2050 
4 G 6 
C14orf
20 -39.4 
chromosome 14 open 
reading frame 20 283629 
9 A 4 STK4 -37.2 serine/threonine kinase 4 6789 
11 B 4 EGFR -36.5 
epidermal growth factor 
receptor (erythroblastic 
leukemia viral (v-erb-b) 
oncogene homolog, avian) 1956 
12 H 10 
ACVRL
1 -36.2 
activin A receptor type II-like 
1 94 
11 H 6 YES1 -36.2 
v-yes-1 Yamaguchi sarcoma 
viral oncogene homolog 1 7525 
11 B 11 EPHA8 -35.6 EphA8 2046 
9 A 2 STK3 -35.0 
serine/threonine kinase 3 
(STE20 homolog, yeast) 6788 
11 B 7 EPHA3 -34.9 EphA3 2042 
11 B 2 DDR2 -34.1 
discoidin domain receptor 
family, member 2 4921 
7 B 4 CDKL2 -33.8 
cyclin-dependent kinase-like 
2 (CDC2-related kinase) 8999 
7 C 6 ERK8 -33.7   225689 
11 C 5 EPHB6 -33.2 EphB6 2051 
9 A 1 STK25 -33.1 
serine/threonine kinase 25 
(STE20 homolog, yeast) 10494 
11 B 6 EPHA2 -32.6 EphA2 1969 
17 C 1 
PRKW
NK3 -31.6 
protein kinase, lysine 
deficient 3 65267 
16 G 5 NEK11 -31.4 
NIMA (never in mitosis gene 
a)- related kinase 11 79858 
11 B 3 STYK1 -31.3   55359 
11 D 4 FLT1 -31.2 
fms-related tyrosine kinase 
1 (vascular endothelial 
growth factor/vascular 
permeability factor receptor) 2321 
16 G 1 KIS -30.3   127933 
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16 D 7 ASB10 -30.3 
ankyrin repeat and SOCS 
box-containing 10 136371 
11 C 9 FER -30.2 
fer (fps/fes related) tyrosine 
kinase (phosphoprotein 
NCP94) 2241 
4 F 5 CAMK4 -30.2 
calcium/calmodulin-
dependent protein kinase IV 814 
4 F 6 CASK -29.9 
calcium/calmodulin-
dependent serine protein 
kinase (MAGUK family) 8573 
17 B 8 ULK1 -29.7 
unc-51-like kinase 1 (C. 
elegans) 8408 
11 C 3 EPHB3 -29.6 EphB3 2049 
11 C 11 FGFR2 -29.4 
fibroblast growth factor 
receptor 2 (bacteria-
expressed kinase, 
keratinocyte growth factor 
receptor, craniofacial 
dysostosis 1, Crouzon 
syndrome, Pfeiffer 
syndrome, Jackson-Weiss 
syndrome) 2263 
11 H 8 INSRR -29.4 
insulin receptor-related 
receptor 3645 
7 C 7 HIPK4 -28.9 
homeodomain interacting 
protein kinase 4 147746 
16 D 11 
TP53R
K -28.9 TP53 regulating kinase 112858 
7 B 8 CLK2 -28.8 CDC-like kinase 2 1196 
11 H 5 TYRO3 -28.5 
TYRO3 protein tyrosine 
kinase 7301 
21 B 3 PKLR -28.5 
pyruvate kinase, liver and 
RBC 5313 
11 B 5 EPHA1 -28.4 EphA1 2041 
7 B 6 CDKL5 -28.0 
cyclin-dependent kinase-like 
5 6792 
13 D 1 ZAK -28.0   51776 
7 B 10 CLK4 -28.0 CDC-like kinase 4 57396 
8 G 4 
MAP3K
8 -27.8 
mitogen-activated protein 
kinase kinase kinase 8 1326 
11 H 7 FES -27.4 feline sarcoma oncogene 2242 
5 A 5 
PRKAA
1 -27.3 
protein kinase, AMP-
activated, alpha 1 catalytic 
subunit 5562 
13 C 1 
MAP3K
13 -26.8 
mitogen-activated protein 
kinase kinase kinase 13 9175 
13 C 2 
MAP3K
7 -26.7 
mitogen-activated protein 
kinase kinase kinase 7 6885 
4 G 5 
KIAA18
11 -26.3   84446 
11 D 10 IGF1R -26.2 
insulin-like growth factor 1 
receptor 3480 
7 D 1 ICK -26.1 
intestinal cell (MAK-like) 
kinase 22858 
20 D 3 
FLJ108
42 -26.1   55750 
16 H 5 PIK3R4 -25.9 
phosphoinositide-3-kinase, 
regulatory subunit 4, p150 30849 
11 D 2 FGFR4 -25.8 
fibroblast growth factor 
receptor 4 2264 
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7 D 9 
MAPK1
4 -25.1 
mitogen-activated protein 
kinase 14 1432 
16 D 9 BUB1 -25.1 
BUB1 budding uninhibited 
by benzimidazoles 1 
homolog (yeast) 699 
7 B 7 CLK1 -25.0 CDC-like kinase 1 1195 
4 H 7 MKNK1 -25.0 
MAP kinase interacting 
serine/threonine kinase 1 8569 
26 D 7 T3JAM -24.7   80342 
7 A 8 CDK4 -24.4 cyclin-dependent kinase 4 1019 
16 D 6 AAK1 -24.3 AP2 associated kinase 1 22848 
4 F 8 
CAMK1
D -24.1 
calcium/calmodulin-
dependent protein kinase ID 57118 
4 G 4 
KIAA09
99 -22.8   23387 
20 B 6 CKB -22.7 creatine kinase, brain 1152 
5 B 6 
STK17
B -22.4 
serine/threonine kinase 17b 
(apoptosis-inducing) 9262 
13 D 3 ANKK1 -22.4 
ankyrin repeat and kinase 
domain containing 1 255239 
5 B 7 
STK22
B -22.4 
serine/threonine kinase 22B 
(spermiogenesis associated) 23617 
5 G 1 
CDC2L
1 -22.3 
cell division cycle 2-like 1 
(PITSLRE proteins) 984 
21 B 2 PRKD2 -22.2   25865 
13 C 3 
MFHAS
1 -22.1 
malignant fibrous 
histiocytoma amplified 
sequence 1 9258 
16 G 7 NEK3 -22.0 
NIMA (never in mitosis gene 
a)-related kinase 3 4752 
13 C 11 
TGFBR
2 -22.0 
transforming growth factor, 
beta receptor II (70/80kDa) 7048 
11 C 8 ERBB4 -21.9 
v-erb-a erythroblastic 
leukemia viral oncogene 
homolog 4 (avian) 2066 
25 C 5 
CDKN2
D -21.5 
cyclin-dependent kinase 
inhibitor 2D (p19, inhibits 
CDK4) 1032 
5 B 3 SNRK -21.4   54861 
4 F 2 
CAMK2
B -21.4 
calcium/calmodulin-
dependent protein kinase 
(CaM kinase) II beta 816 
13 C 10 
TGFBR
1 -21.3 
transforming growth factor, 
beta receptor I (activin A 
receptor type II-like kinase, 
53kDa) 7046 
5 A 6 
PRKAA
2 -21.2 
protein kinase, AMP-
activated, alpha 2 catalytic 
subunit 5563 
5 C 7 
LOC91
807 -20.8   91807 
11 D 5 FLT3 -20.7 
fms-related tyrosine kinase 
3 2322 
17 B 3 TEX14 -20.0 
testis expressed sequence 
14 56155 
7 B 9 CLK3 -19.8 CDC-like kinase 3 1198 
17 A 3 
PRKW
NK2 -18.4 
protein kinase, lysine 
deficient 2 65268 
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5 B 8 
STK22
C -18.1 
serine/threonine kinase 22C 
(spermiogenesis associated) 81629 
5 C 1 TRAD -17.9   11139 
7 D 3 MAK -17.8 
male germ cell-associated 
kinase 4117 
16 H 2 NPR2 -17.2 
natriuretic peptide receptor 
B/guanylate cyclase B 
(atrionatriuretic peptide 
receptor B) 4882 
16 D 10 BUB1B -17.1 
BUB1 budding uninhibited 
by benzimidazoles 1 
homolog beta (yeast) 701 
5 C 4 CHEK1 -16.2 
CHK1 checkpoint homolog 
(S. pombe) 1111 
8 E 11 
FLJ230
74 -16.0   80122 
13 C 4 RAF1 -15.2 
v-raf-1 murine leukemia viral 
oncogene homolog 1 5894 
5 B 9 
STK22
D -14.3 
serine/threonine kinase 22D 
(spermiogenesis associated) 83942 
4 E 10 CAMK1 -13.9 
calcium/calmodulin-
dependent protein kinase I 8536 
8 G 2 
MAP3K
5 -13.2 
mitogen-activated protein 
kinase kinase kinase 5 4217 
5 G 5 
SCGB2
A1 -12.8 
secretoglobin, family 2A, 
member 1 4246 
5 F 3 
CSNK1
G3 -11.9 casein kinase 1, gamma 3 1456 
8 G 11 MST4 -11.6   51765 
5 F 2 
CSNK1
G2 -9.8 casein kinase 1, gamma 2 1455 
5 F 1 
CSNK1
G1 -9.5 casein kinase 1, gamma 1 53944 
25 C 11 
CSNK2
B -9.2 
casein kinase 2, beta 
polipeptide 1460 
26 C 9 
PRKCD
BP -9.2 
protein kinase C, delta 
binding protein 112464 
20 F 9 
MGC26
597 -9.2   206426 
7 A 11 CDK7 -9.0 
cyclin-dependent kinase 7 
(MO15 homolog, Xenopus 
laevis, cdk-activating kinase) 1022 
20 F 3 ITPKA -8.6 
inositol 1,4,5-trisphosphate 
3-kinase A 3706 
26 D 4 SKIV2L -8.6 
superkiller viralicidic activity 
2-like (S. cerevisiae) 6499 
7 D 7 
MAPK1
2 -8.5 
mitogen-activated protein 
kinase 12 6300 
14 D 1 BRD2 -8.3 bromodomain containing 2 6046 
7 A 10 CDK6 -8.1 cyclin-dependent kinase 6 1021 
26 B 6 PKIA -7.7 
protein kinase (cAMP-
dependent, catalytic) 
inhibitor alpha 5569 
25 H 1 OSRF -7.6   23548 
13 B 3 IRAK3 -7.6 
interleukin-1 receptor-
associated kinase 3 11213 
21 C 4 SPHK2 -7.5 sphingosine kinase 2 56848 
2 D 4 CDC42 -7.4 CDC42 binding protein 9578 
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BPB kinase beta (DMPK-like) 
11 G 6 RYK -7.2 
RYK receptor-like tyrosine 
kinase 6259 
8 F 2 JIK -7.1   51347 
25 G 2 
MAPK8
IP3 -6.6 
mitogen-activated protein 
kinase 8 interacting protein 
3 23162 
17 A 1 
RNASE
L -6.6 
ribonuclease L (2,5-
oligoisoadenylate 
synthetase-dependent) 6041 
8 F 3 
MAP2K
1 -6.3 
mitogen-activated protein 
kinase kinase 1 5604 
14 C 11 BCR -6.0 breakpoint cluster region 613 
25 C 7 CIB2 -5.8 
calcium and integrin binding 
family member 2 10518 
2 F 8 PKN2 -5.8 protein kinase N2 5586 
5 E 9 
CSNK1
A1 -5.7 casein kinase 1, alpha 1 1452 
8 F 1 LYK5 -5.7   92335 
11 E 6 KIT -5.4 
v-kit Hardy-Zuckerman 4 
feline sarcoma viral 
oncogene homolog 3815 
8 H 2 MYO3B -5.3 myosin IIIB 140469 
12 H 11 
ACVR1
C -5.1 activin A receptor, type IC 130399 
26 B 2 PIK3R3 -5.1 
phosphoinositide-3-kinase, 
regulatory subunit, 
polypeptide 3 (p55, gamma) 8503 
17 B 6 TOPK -4.7   55872 
13 C 6 RIPK2 -4.7 
receptor-interacting serine-
threonine kinase 2 8767 
8 H 5 PAK2 -4.5 
p21 (CDKN1A)-activated 
kinase 2 5062 
7 B 11 CRK7 -4.2   51755 
21 B 5 PMVK -4.1 phosphomevalonate kinase 10654 
25 G 1 
MAPK8
IP2 -4.1 
mitogen-activated protein 
kinase 8 interacting protein 
2 23542 
2 D 9 GRK5 -4.1 
G protein-coupled receptor 
kinase 5 2869 
5 F 8 VRK2 -4.1 vaccinia related kinase 2 7444 
20 F 6 KHK -4.1 
ketohexokinase 
(fructokinase) 3795 
14 D 5 CABC1 -4.1 
chaperone, ABC1 activity of 
bc1 complex like (S. pombe) 56997 
25 E 9 
LOC28
3846 -3.9   283846 
14 D 11 HSPB8 -3.7 heat shock 22kDa protein 8 26353 
13 C 7 RIPK3 -3.7 
receptor-interacting serine-
threonine kinase 3 11035 
21 C 9 TPK1 -3.5 
thiamin pyrophosphokinase 
1 27010 
13 B 7 LIMK2 -3.5 LIM domain kinase 2 3985 
5 A 10 PSKH1 -3.2 protein serine kinase H1 5681 
2 H 8 SGKL -3.1 
serum/glucocorticoid 
regulated kinase-like 23678 
26 B 4 
PIP5K1
C -3.1 
phosphatidylinositol-4-
phosphate 5-kinase, type I, 23396 
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gamma 
2 D 8 GRK4 -2.9 
G protein-coupled receptor 
kinase 4 2868 
20 F 11 MRC2 -2.9 mannose receptor, C type 2 9902 
13 A 2 RIPK4 -2.9 
receptor-interacting serine-
threonine kinase 4 54101 
8 F 6 
MAP2K
4 -2.8 
mitogen-activated protein 
kinase kinase 4 6416 
7 F 2 CDK11 -2.7 
cyclin-dependent kinase 
(CDC2-like) 11 23097 
25 C 8 CIB3 -2.7 
calcium and integrin binding 
family member 3 117286 
8 H 1 MYO3A -2.6 myosin IIIA 53904 
14 E 11 PRKDC -2.4 
protein kinase, DNA-
activated, catalytic 
polypeptide 5591 
20 F 1 IHPK3 -2.4 
inositol hexaphosphate 
kinase 3 117283 
25 C 10 CRIM1 -2.3 cysteine-rich motor neuron 1 51232 
26 B 3 
PIP5K1
B -2.3 
phosphatidylinositol-4-
phosphate 5-kinase, type I, 
beta 8395 
17 B 5 TLK2 -2.3 tousled-like kinase 2 11011 
26 B 5 
PIP5KL
1 -2.2 
phosphatidylinositol-4-
phosphate 5-kinase-like 1 138429 
14 D 6 EEF2K -2.1 
eukaryotic elongation factor-
2 kinase 29904 
13 A 3 ARAF1 -2.0 
v-raf murine sarcoma 3611 
viral oncogene homolog 1 369 
20 F 5 ITPKC -1.9 
inositol 1,4,5-trisphosphate 
3-kinase C 80271 
14 D 4 BRDT -1.9 bromodomain, testis-specific 676 
8 F 4 
MAP2K
2 -1.7 
mitogen-activated protein 
kinase kinase 2 5605 
26 C 7 
PRKCA
BP -1.4 
protein kinase C, alpha 
binding protein 9463 
20 G 2 NAGK -1.0 N-acetylglucosamine kinase 55577 
7 D 11 MAPK6 -0.8 
mitogen-activated protein 
kinase 6 5597 
7 E 9 RAGE -0.6 renal tumor antigen 5891 
26 C 5 
PRKAR
1B -0.6 
protein kinase, cAMP-
dependent, regulatory, type 
I, beta 5575 
14 D 10 FRAP1 -0.5 
FK506 binding protein 12-
rapamycin associated 
protein 1 2475 
2 E 8 PKN3 -0.4 protein kinase N3 29941 
4 E 8 TRIB3 0.0 
tribbles homolog 3 
(Drosophila) 57761 
2 F 7 PKN1 0.1 protein kinase N1 5585 
20 H 10 
PFKFB
4 0.2 
6-phosphofructo-2-
kinase/fructose-2,6-
biphosphatase 4 5210 
26 A 9 
PIK3C
D 0.3 
phosphoinositide-3-kinase, 
catalytic, delta polypeptide 5293 
26 D 1 SCAP1 0.4 
src family associated 
phosphoprotein 1 8631 
20 B 11 DCK 0.5 deoxycytidine kinase 1633 
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2 E 7 PDPK1 0.7 
3-phosphoinositide 
dependent protein kinase-1 5170 
14 D 9 ADCK4 0.8 
aarF domain containing 
kinase 4 79934 
7 E 8 
PRPF4
B 1.0 
PRP4 pre-mRNA processing 
factor 4 homolog B (yeast) 8899 
20 D 5 
FN3KR
P 1.2   79672 
26 A 2 
PIK3AP
1 1.2 
phosphoinositide-3-kinase 
adaptor protein 1 118788 
16 E 6 
CSNK2
A1 1.3 
casein kinase 2, alpha 1 
polypeptide 1457 
21 C 2 RBKS 2.3 Ribokinase 64080 
26 C 11 
PRKRI
R 2.8 
protein-kinase, interferon-
inducible double stranded 
RNA dependent inhibitor, 
repressor of (P58 repressor) 5612 
14 E 10 PDK4 3.0 
pyruvate dehydrogenase 
kinase, isoenzyme 4 5166 
2 D 7 
FLJ250
06 3.1   124923 
20 D 8 
PIP5K2
C 3.4 
phosphatidylinositol-4-
phosphate 5-kinase, type II, 
gamma 79837 
26 B 11 
PRKAB
2 3.5 
protein kinase, AMP-
activated, beta 2 non-
catalytic subunit 5565 
14 D 7 FASTK 3.5   10922 
2 F 2 
PRKCB
1 3.7 protein kinase C, beta 1 5579 
20 F 8 LCK 4.3 
lymphocyte-specific protein 
tyrosine kinase 3932 
21 A 9 
PIP5K1
A 4.4 
phosphatidylinositol-4-
phosphate 5-kinase, type I, 
alpha 8394 
13 A 6 BMPR2 4.5 
bone morphogenetic protein 
receptor, type II 
(serine/threonine kinase) 659 
7 E 11 STK23 4.9 serine/threonine kinase 23 26576 
13 A 5 
BMPR1
B 5.2 
bone morphogenetic protein 
receptor, type IB 658 
8 H 7 PAK4 5.9 
p21(CDKN1A)-activated 
kinase 4 10298 
14 D 8 RIOK2 6.0 RIO kinase 2 (yeast) 55781 
26 D 2 
SH3KB
P1 6.3 
SH3-domain kinase binding 
protein 1 30011 
16 E 7 
CSNK2
A2 6.5 
casein kinase 2, alpha prime 
polypeptide 1459 
13 A 4 
BMPR1
A 8.7 
bone morphogenetic protein 
receptor, type IA 657 
26 D 5 SKP2 8.9 
S-phase kinase-associated 
protein 2 (p45) 6502 
20 B 9 CKMT2 9.2 
creatine kinase, 
mitochondrial 2 (sarcomeric) 1160 
25 F 8 
MAP3K
7IP2 11.1 
mitogen-activated protein 
kinase kinase kinase 7 
interacting protein 2 23118 
2 F 1 PRKCA 11.5 protein kinase C, alpha 5578 
25 F 7 MAP3K 15.0 mitogen-activated protein 10454 
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7IP1 kinase kinase kinase 7 
interacting protein 1 
7 A 5 CDK10 15.8 
cyclin-dependent kinase 
(CDC2-like) 10 8558 
25 B 5 AKAP9 31.1 
A kinase (PRKA) anchor 
protein (yotiao) 9 10142 
25 B 4 
AKAP8
L 31.1 
A kinase (PRKA) anchor 
protein 8-like 26993 
25 D 11 IHPK2 32.9 
inositol hexaphosphate 
kinase 2 51447 
25 B 1 AKAP6 33.2 
A kinase (PRKA) anchor 
protein 6 9472 
2 F 4 PRKCE 37.6 protein kinase C, epsilon 5581 
25 A 3 AKAP1 46.4 
A kinase (PRKA) anchor 
protein 1 8165 
20 E 9 HK2 49.6 hexokinase 2 3099 
25 B 8 CALM1 72.9 
calmodulin 1 (phosphorylase 
kinase, delta) 801 
25 B 9 CALM2 130.0 
calmodulin 2 (phosphorylase 
kinase, delta) 805 
 
  
 
Table1. The table shows 217 kinases which RNAi produce an effect ranging from -50% to 130% on mitochondrial 
calcium uptake. They are all the mean of the effect of three difference siRNA sequences. 
 
Figure 2 
                                
Fig.2  A histogram showing the effect of each kinase (217 kinases with three fold redundancy) on mitochondrial 
calcium uptake, candidates with average increasing or reducing effect more than 20% are enlightened in red boxes. 
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217 kinases x three siRNAs 
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According to prior studies Transforming growth factor–β (TGF-β) has been implicated as a key 
factor in mediating many cellular processes and it has also been demonstrated its ability to impair 
cytosolic calcium concentration which in some cases may result from the downregulation of the 
IP3 receptor Ca
2+
 channels (IP3Rs). Pieces of evidence collected from many different groups indeed 
demonstrate that the normal mobilization of intracellular Ca
2+
 stores is reduced in diabetic aortic 
and proglomerular smooth muscle cells and the alteration is mediated by TGF-β.  We decided to 
concentrate our attention on the study of TGF-β role on mitochondrial calcium uptake and the 
starting point was coming from the preliminary data collected from the above reported screen 
which shows that  calcium uptake is reduced of 22% by both the isofoms of TGF-β receptor (TGF-
βR I and II) .  
 
Mitochondrial Calcium signaling is affected by TGF- β receptor inhibition 
The first experiment to be performed was the reproduction of the siRNAs effect on a larger scale.  
HeLa cells were transfected with the mitochondrially targeted aequorin probe and a reconstituted 
with the aequorin co-factor coelenterazine; Ca
2+
 transients were trigger by maximal dose of 
histamine 100μM, luminescence was measured and then converted in [Ca
2+
]. Control coverslips, 
treated with DMSO, were compared to TGF-β receptor chemical inhibitors SB431542 5μM 
(inhibitor of TGF-β receptors I and II, signaling mainly through Smad2/3) and Dorsomorphin (DM) 
10μM (inhibitor of BMP activated receptors, signaling mainly through Smad1/5/8) treated cells. 
The time of treatment was reduced from 16 hours to 4 hours to 10 minutes in order to observe 
the acute effect on mitochondrial calcium of the chemical silencing of  TGF-β receptor signaling 
cascade. As shown in figure 3A, B and C, the chemical inhibition of TGF-β receptors causes an 
evident reduction of mitochondrial calcium uptake:  while in control cells the mitochondrial 
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calcium transient observed corresponded to [Ca
2+
]mt of 128+14.6 μM, after overnight treatment 
with SB431542 and Dorsomorphin [Ca
2+
]mt was reduced to 99.5+17.6μM and 72+17.6μM 
respectively. 
Figure 3 
 
Fig.3 HeLa cells were transfected with mitochondrially-targeted aequorin (mtAEQ). 36 hours after transfection, 
mitochondrial Ca
2+
 uptake evoked by Histamine 100μM, was measured in three different conditions : A) overnight 
treatment with SB 431542 (SB) 5μM (inhibitor of TGF-β receptors I and II, signaling mainly through Smad2/3) and 
Dorsomorphin (DM) 10μM (inhibitor of BMP activated receptors, signaling through Smad1/5/8);  B) 4 hours treatment  
and  C) 10 minutes  treatment with the same agents. The observed reduction in mitochondrial Ca
2+
 response produced 
by these treatments was the first indication of a role of TGF-β signalling in the regulation of mitochondrial Ca
2+
 
handling. 
 
Thus the effect of two different inhibitors, working on two different subfamily of TGF-β receptor is 
qualitatively the same, differences in the amplitude of reduction are probably linked to the greater 
number of inhibited BMP receptors than TGF-β receptors, or differences in receptor affinity to the 
two chemical compounds.  
HeLa cells were transfected with cytosol localizing aequorin Ca
2+
-probe (CytAeq) and low affinity 
ER-targeted aequorin based Ca
2+
-probe, cytosolic and Endoplasmic Reticulum calcium 
concentration were measured and representative experiments are shown in Fig.4. These results 
excluded that the mitochondrial calcium uptake reduction observed could be explained by general  
Ca
2+ 
handling impairment nor by defective storing within the major intracellular calcium store, 
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since no significant difference has been recorded in the two compartments. These data strongly 
supported the hypothesis of a direct activity of TGF-β on mitochondria while the homeostasis of 
this ion in the other compartment remained affected.  
Figure 4 
 
 
 
Fig.4 ER and cytosolic Ca
2+
 measurements with targeted aequorin probes. In both compartments, pretreatment with 
SB and DM did not modify either the resting values nor the peak (cytosol) or decrease (ER) caused by stimulation with 
Histamine 100μM. 
 
Mitochondrial membrane potential  (Δψmt ) was measured in HeLa cells in order to test whether 
mitochondrial calcium uptake reduction is dependent from mitochondrial respiratory chain 
activity. In living cells  Δψmt was measured using tetramethyl rhodamine methyl ester (TMRM), a 
fluorescent lipophilic cation that accumulates in the mitochondrial matrix in a Δψmt-dependent 
way. The fluorescence intensity of TMRM in individual cell was measured using laser scanning 
microscopy. To measure and compare the potential-dependent staining of TMRM of different 
conditions, cells were incubated with 1 μM FCCP, a protonophore that collapses the Δψmt. The loss 
of TMRM fluorescence was used to obtain quantitative analysis of Δψmt. The representative traces 
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in fig. 5 showed that overnight treatments with SB 5μM and DM 10 μM strongly reduced TMRM 
fluorescence basal level (-35 + 8.2% and -42 + 12.7%) if compared with untreated controls. Since it 
is well established the notion that  Δψmt drives mitochondrial uptake of Ca
2+
, these results 
appeared to be consistent with the previous observation about the mitochondrial calcium uptake 
impairment, obtained with aequorin measurements after TGF-β receptors inhibition. 
Figure 5 
 
 
 
Fig.5 The electrical potential across the mitochondrial inner membrane (Δψmt ) was measured with Tetramethyl 
Rhodamine Methil Ester (TMRM). Mitochondrial TMRM loading  at the steady state was significatively decreased by 
overnight treatment with SB 5μM and DM 10 μM (A, left representative traces; right, quantification in the whole array 
of analyzed cells). Upon treatment with FCCP, all traces reached the same background level. Figure B shows 
representative images of HeLa cells incubated with TMRM 10nM for 20 minutes and DMSO, SB 5μM and DM 10μM, 
fluorescent intesity of TMRM  was detected with laser scanning  microscopy. 
 
 
Along the same line were the measurements of mitochondrial ATP production carried out by 
means of ATP luciferase probe targeted to the mitochondrial compartment. The method is based 
on the reaction of luciferase with the substrate luciferin in presence of oxygen, being the following 
light emission a linear function of ATP concentration in a range between 10
-3
 and 10
-2
 M. HeLa 
cells were transfected with mitochondrial targeted luciferase (mtLUC)  and 24 later coverslips 
were transferred to the 37°C termostated chamber of a luminometer and perfused with a Krebs 
Ringer Buffer containing 20μM Luciferin. During the preliminary phase of equilibration, light 
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emission was in the range of 12000-17000 cps versus a background lower than 10 cps, cellular 
response was evoked by the agonist Histamine 100μM added to the perfusion medium. As 
previously reported (Jouaville L.S., 1999), agonist-dependent [Ca
2+
] increases in the mitochondrial 
matrix cause an increase in ATP levels, both in the mitochondria (Fig.6) and in the cytosol (data not 
shown). This was mainly attributed to the stimulation of Ca
2+
-dependent dehydrogenases. We 
evaluated the effect on level of ATP production produced by acute treatment of HeLa cells with SB 
5μM and DM 10 μM. In treated cells, in agreement with our previous results on calcium signaling, 
ATP  production is drastically reduced (fig.6). The impairment of calcium uptake occurring in  the 
organelle after TGF-β receptors inhibition correlates with a minor Ca
2+
-mediated stimulation of 
matrix dehidrogenases which leads to the reduction of ATP synthesis observed (-42.8+4.2% for SB 
and -37.1+6.1% for DM ).  
Figure 6 
 
Fig.6 A mitochondrially targeted chimera of ATP-sensitive photoprotein Luciferase (mtLUC) was exploited to 
dynamically monitore ATP synthesis within the mitochondrial subcellular compartment. HeLa cells were seeded on 
coverslips and grown in DMEM plus 10% FBS. Two days before the ATP measurements, the two groups of cells were 
transfected with  mtLUC probe, the following day one set of coverslips was treated with dmso (controls), one set with 
SB 5μM and one set with DM 10uM. For the measurements, the cells were rinsed twice with KRB, then transferred to 
the luminometer chamber and perfused with KRB supplemented with glucose 5,5mM, calcium 1mM and Luciferin 
20μM. 60 seconds were allowed for equilibration in the new medium, then ATP production was triggered by 
supplementing the perfusion buffer with Histamine 100μM. In presence of TGF-β receptors inhibitors ATP production 
appeared to be reduce of  -42.8+4.2% in the case of  SB and of 37.1+6.1% for DM. 
 
60sec 
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TGF-β receptors silencing by means of specific siRNA plasmids 
Mitochondrial network and the biophysical properties of mitochondrial calcium uptake have been 
studied in detail and since it has been demonstrated its high sensitivity to lipholic molecules. In 
order to evaluate the real effect of TGF-β receptors inhibition, without the usage of chemical 
compounds dissolved into DMSO, we decided to built up siRNA plasmids to downregulate  TGF-β 
receptor isoforms through RNA interference techniques, so doing we would get rid of any possible 
non-specific effect due to chemical treatment. Two different sequences for TGF-β receptor I and II 
were cloned into pSuper Vector (siRNA TGF-βRI and siRNA TGF-βRII) and the silencing capacity of 
the two most efficient plasmids, chosen for further experiments, is shown in figure 7. 
 
Figure 7  
                                              
Fig.7 HeLa cells were transfected with small interfering (siRNA ) plasmids created using a pSuper vector. We obtained 
two different  sequences  cloned in the expression vector, efficently silencing target genes of TGF-β receptor I and II. 
The western blot shows the most effective sequences we used to perform the following experiments. 
 
 
Intracellular calcium homeostasis was then analized in HeLa cells after co-transfection of TGF-ΒR I 
and II siRNAs and aequorin probes specifically targeted to mitochondria, Endoplasmic Reticulum 
and cytosol. 
The effect is reported in the panel below (fig. 8), where it is evident the peculiar reduction of 
mitochondrial Ca
2+
 uptake while the other two compartment appeared to be unaffected. 
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Figure 8 
 
Fig.8 Calcium measurements were carried out in HeLa cells  co-transfected with the siRNAs of the two  different 
isoforms of TGF-β receptor and aequorin-based Ca
2+
 probes. The data confirmed that  mitochondrial Ca
2+
 response 
after stimulation was significantly decreased upon suppression of TGF-β signaling, whereas cytosolic and ER Ca
2+
 
handling was unaffected. 
 
Mitochondrial membrane potential (Δψmt) was measured in presence of DMSO (as negative 
control, black line), SB 5μM (as positive control, orange line) and after 36 hours co-transfection 
with the siRNA plasmids of the two different isoforms of TGF-β receptor.  
Comparing the effect exerted by two different tools to achieve TGF-β pathway inactivation, we 
could assess that they were both on the same line of what had been observed by aequorin 
measurements, Δψmt was strongly reduced and mitochondrial  Ca
2+ 
uptake along with it. (Fig. 9) 
Fig. 9 
 
Fig. 9 Mitochondrial membranepotential (Δψmt) was measured with TMRM in untreated HeLa cells (black trace) or 
after TGF-β receptor inhibition by means of SB 5μM (orange line) or siRNA silencing (pink line). 
control 
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The effect on mitochondrial Ca
2+
 uptake was thus confirmed by direct specific intraorganelle 
measurements thanks to aequorin probes, indirectly exploting Luciferase probe specifically 
targeted to mitochondrial which measured ATP production and finally through TMRM analysis of 
potential across the mitochondrial membrane. 
 
Subcellular distribution of Smad proteins 
The question we had to answer then was: which was molecular mechanism ruling the effect ?  
Looking for possible molecular characters we decided to define subcellular localization of TGF-β 
downstream effectors: the Smad proteins. 
Among the huge family of these intracellular transducers we focused our attention on isoforms 2 
and 3 because from previous work (Jullig M., 2003) they were demonstrated to be the members 
with higher mitochondrial distribution. 
Mitochondrial cellular fractioning was performed as described in Materials and Methods on HeLa 
cells to compare Smads localization in mito crude fraction with or without TGF-β receptors 
inactivation by means of SB treatment. 
As it is shown in fig. 10 Smad2/3 was observed in mito crude of HeLa cells, interestingly its 
phosphorylated fraction appeared to be delocalized from mitochondria after the treatment 
applied.  
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Figure 10 
                                 
Fig.10 Subcellular localization of  Smad proteins, TGF-β receptor effectors. Western blots of subcellular fractions 
shows mitochondrial distribution of Smad2/3 that was decreased by SB 5μM  treatment. Interestingly, we observed 
the almost complete absence of the phosphorylated protein in mitochondria of HeLa cells treated with the inhibitor. 
 
We thus speculated that most likely the equilibrium between the phosphorylated and 
unphosphorylated fraction of Smad2/3 could be linked to those mitochondrial events produced by 
chemical or biological inhibition of TGF-β receptors, described before.  
 If the mitochondrial delocalization of the specific isoform of Smad proteins was responsible for 
the impairment of mitochondrial functionality, then the question was: what about the biological 
mechanism? 
Two different possibilities could be envisioned.  
In the first one the phosphorylated pool of Smad could act favouring calcium transfer between the 
major intracellular store, the Endoplasmic Reticulum and mitochondria, thus we measure calcium 
transient by means of mitochondrial aequorin probe in presence of TGF-β or not. What we 
observed is shown in figure 11, and despite what was expected, no increase has been recorded in 
mitochondrial calcium uptake. 
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Figure 11 
A                                                                                     B                                                                                                                            
                                                                                                                                             
Fig. 11  A) Mitochondrial calcium transients were measured in HeLa cells in presence of TGF-β (1h 1ng/ml), SB (5 μM  
20min) or not. Since no significative difference was observed  comparing control coverslips and TGF-β treated ones 
(control 120+ 5.4μM, TGF-β 118+6.7 μM, SB 88+ 2.4μM) we could asses that increasing the phosphorylated fraction of 
Smad proteins can not be considered responsible for mitochondrial calcium uptake regulation. B) Western Blot 
analysis of Smad2/3 and Phospho-Smad3 levels In presence of the same two treatments applied for calcium 
measurements 
 
In the second scenario, we speculated that the unphosphorylated fraction of Smads could be the 
true character behind the mitochondrial effect. Indeed inhibiting the plasma membrane receptors 
by chemical treatments or SiRNA plasmid, the unphosphorylated protein would accumulate and 
the mitochondrial fraction would increase as a consequence. Therefore if it was true that 
accumulation of Smads at the mitochondria negatively regulates calcium uptake, inhibiting regular 
gene expression of Smad proteins by means of specific SiRNA duplexes would revert the effect 
observed treating  HeLa cells with TGF-β  receptors inhibitor. Thus we co-transfected HeLa cells 
with ShRNA of Smad2/3 and Smad4 and mitochondrial aequorin probe in order to measure 
calcium transients after agonist stimulation. The data collected are shown in figure 12 and as 
expected mitochondrial calcium uptake is clearly increased where Smad proteins have been 
silenced.   
 
 
Dmso     SB     TGF-β 
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Figure 12 
A                                                                                                B 
                                                                                                  
Fig.12 A) Mitochondrial calcium transients were measured in HeLa cells co-transfected with two different ShRNAs of 
Smad2/3 or Smad4,  and mitochondrial aequorin. As shown in  panel A silencing Smad proteins enhances 
mitochondrial calcium uptake. (Scrambled 82+ 6.1μM, SiRNA Smad2/3 I 113+ 7.2μM, SiRNA Smad2/3 II 120+ 4.2μM, 
SiRNA Smad4 I 121+ 9.2μM, SiRNA Smad4 II 125+ 6.2μM). B) Western Blot analysis of Smad2/3 and Smad4 levels In 
presence of their specific ShRNAs. 
 
At this point, the study of a more physiological system than HeLa cells was fundamental, for this 
reason we wanted to analyze intracellular Smads distribution in mouse liver. 
Recently a very accurate method has been described by Wieckowsky and coworkers to obtain 
mitochondrial purification from different animal tissues by gradient centrifugation in order to 
separate pure mitochondria from the so called “mitochondria-associated membrane” (MAM) (fig. 
13) (Wieckowsky M., 2009). Intriguingly this fraction would prove to be not only mere 
contamination of pure mitochondria but also a very interesting mitochondrial subfraction, indeed 
since 1990 the specific mitochondrial regions showing close proximity to the ER cisternae were 
referred as MAMs by Vance et al. (Vance J.E., 1990). Although they have been firstly described as 
the headquarters of lipid transfer, today it is widely accepted the notion that MAMs are also 
involved in rapid movement of Ca
2+ 
ions between ER and mitochondria. So doing they play a 
fundamental role in the coordination of ATP production through the activation of mitochondrial 
dehydrogenase as well as the activation of the cell death program (Berridge M.J., 2002). The 
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shaping of the ER-mitochondrial network can be affected by bounding proteins and physiological 
ligands indeed recently Hajnoczky and coworkers demonstrated that exposure to TGFβ affects Ca
2+  
transfer to the mitochondria (Hajnoczky G., 2008).  
Figure 13 
       
 
Fig. 13 A) Isolation of Mitochondria Associated Membranes (MAMs) from animal tissues and cells  (Wieckowsky M., 
2009) B) Combined 3D imaging of mitochondria and ER in a HeLa cell transiently expressing mtGFP(Y66H,Y145F) and 
erGFP(S65T). The two 3D images were processed  and superimposed. The mitochondrial and ER images are 
represented in red and green, respectively; 
the overlaps of the two images are white and constitute the microdomains called MAMs. (Rizzuto R., 1998) 
  
Mouse liver were homogenized, and crude mitochondrial fraction (8,000g pellet) was subjected to 
separation on a 30% self-generated Percoll gradient as described previously (Vance J.E., 1990). A 
low-density band (denoted as MAM fraction, fig.14A) was collected and analysed by 
immunoblotting.  
Specific markers were chosen for each different fraction (IP3 Receptor 3 for MAM and ER fractions, 
VDAC2 for pure and crude mitochondria, Sigma1 Receptor for MAM and β-actin as cytosolic 
protein, see  figure 14), and from prelimary results Smad2/3 appeared to be clearly localized in the 
mitochondria and in particular into the MAM fraction.  
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Figure 14 
                                                 
Fig.14 A more extensive subcellular fractionation in mouse liver shows the presence of Smads in the MAM fraction, 
thus suggesting a direct regulatory role exerted in this signaling domain. 
 
 
The evidence of Smad2/3 presence in the MAMs obtained from a physiological system such as 
mouse liver, is the starting point of a wide work that would lead to the understandment of a new 
role of TGF-β signaling pathway in the orchestration of mitochondrial calcium signaling. 
Next step would be the analysis of Smads and phospho-Smads delocalization in vivo after TGF-β 
receptor inhibition or activation by means of mouse liver perfusion techniques carried out in 
presence of chemical compounds. Moreover it would be necessary the research of Smads 
molecular interactors by means of co-immunoprecipitation and Blue Native assays. 
Hence, further study will be done to assess a possible direct mitochondrial activity of Smad 
proteins on the organelle calcium homeostasis.  
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DISCUSSION 
Preliminary results obtained by a screening based on a human kinases library, showed that 
silencing TGF-β Receptors by means of siRNA duplexes, exerted a clear effect on mitochondrial 
calcium homeostasis. This starting information was then exploited to unravel the molecular 
mechanism by which mitochondria could orchestrate intracellular calcium homeostasis. 
TGF-β signaling has been widely studied and although its transcriptional activity is today well 
understood, less efforts have been made to investigate its non-nuclear functions which are still 
quite unknown. 
We thus decided to go deeply through this study, since according to previous works a 
transcriptional-independent activity of TGF-β cascade had already been observed. First of all, 
many different groups are engaged in the study of TGF-β role in the regulation of the intrinsic 
pathway leading to apoptosis. Gottfried in 2004 demonstrated TGF-β activation of ARTS, a 
proapoptotic protein localized in the mitochondria. Wang et al., in 2008 published the observation 
that TGF-β treatment could generate reactive oxygen species (ROS) and mitochondrial membrane 
potential loss in epithelial cell.  
Concerning calcium homeostasis, recent works showed that TGF-β could reduce IP3 Receptor 1 
calcium release from ER in diabetic aortic and proglomerular smooth muscle cells.  
The first step we took, was to obtain a more complete scenario about intracellular calcium 
homeostasis  after TGF-β signaling inhibition. Overexpressing  aequorin probe in HeLa cells, we 
observed that mitochondrial calcium uptake was impaired when TGF-β signaling was inhibited by 
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chemical treatments, whereas Endoplasmic Reticulum and cytosolic calcium handling was 
unaffected.  
The same scenario was there inhibiting TGF-β signaling both by molecular inhibitors acute 
treatment and by transfecting TGF-β receptor siRNA plasmids into the cells. 
Mitochondrial functionality was consistently affected in the same conditions, since we observed 
the reduction of mitochondrial membrane potential and also the ATP production resulted 
significantly impaired. 
Then we focused on how this effect was achieved. 
The biochemical meaning of TGF-β receptors inhibition is the reduction of the phosphorylated 
fraction of TGF-β receptors downstream effectors: the Smad proteins. Therefore we speculated 
that the mitochondrial specific effect could be the result of two different situation.  
According to the first one, reduction of Smad phosphorylation could be direct source of the 
mitochondrial effect, under the hypothesis that the phosphorylated Smad could positively control 
calcium transfer between the ER and mitochondrial. Thus we  hypothesized that the less is the 
amount of phospho-Smad working at the mitochondria, the less these organelles are exposed to 
high Ca
2+
 concentration generated at the mouth of IP3Rs. As described in the introduction of this 
work, this could explain the reduction in mitochondrial calcium transient after agonist stimulation.  
The second hypothesis envisioned the non-phosphorylated fraction of Smad proteins as 
responsible for a negative regulation of ER-mitochondrial contacts. Indeed switching off TGF-β 
receptors avtivity, the intracellular amount of non-pshorylated  Smads increased and consequently 
the equilibrium between the nuclear and mitochondrial (and cytosolic) pools of these proteins, 
most likely would shift toward the mitochondrial translocation. Blocking TGF-β receptors activity a 
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great amount of Smad would be potentially disposable for mitochondrial accumulation where it 
exerted a specific effect on calcium transients.        
We thus decided to silence, by means of short hairpin RNA interference, the total amount of 
specific isoforms of Smads, we chose to silence Smad 2/3 and Smad 4, members of a great family 
of nuclear factors, which are described to be localized into the mitochondria (which was confirmed 
in our lab also). So thanks to Smad2/3 and Smad4 shSiRNAs, we measured calcium transients in 
HeLa cells and we observed a clear augmentation in mitochondrial calcium uptake in coverslips 
where normal transcription of Smad proteins was blocked, compared to scrambled controls. This 
observation supported the second hypothesis : the non phosphorylated Smads exerted negative regulation 
on ER-mitochondrial transfer. 
On the other hand, we treated HeLa cells with TGF-β polypeptide and measured mitochondrial 
calcium uptake. If the first hypothesis had been true, the potentiation of TGF-β receptors activity 
would have increased the phosphorylation of Smad proteins and consequently the mitochondrial 
impairment described so far would have had to be inverted. Indeed if phospho-Smad was a 
positive regulator of mitochondrial function, in TGF-β treated coverslips we should have observed 
a mitochondrial calcium uptake enhancement. 
However no increase was recorded to further support the idea that it was not the phosphorylated 
but the non-phosphorylated pool of Smads which was responsible for a negative control of ER-
mitochondria contacts. 
Moreover subcellular fractionation obtained from mouse liver, showed that a good fraction of 
Smad2/3 protein is localized in the MAM, the well described contact sites between ER and 
mitochondria. 
  
63 
Although the molecular mechanism that controls different distribution of Smads are still 
completely unknown (apart from the classical pathway ruling gene transcription) according to our 
data, a new role for these proteins has been demonstrated, which is independent from the 
nucleus whereas it appears to be associated to the mitochondria. 
Aequorin probe measurements, carried out in living cells, revealed a clear engagement of TGF-β in 
regulating mitochondrial calcium transient evoked by agonists stimulation. 
Moreover biochemical studies demonstrated that there is a specific localization of Smad proteins 
both in crude mitochondrial fraction and in the low density mitochondrial associated membranes 
(MAMs) where, most likely, they could participate in complexes with other signaling partners. 
In conclusion this work highlights a quite unexplored signaling pathway for TGF-β, telling that 
Smad proteins can directly regulate mitochondrial calcium homeostasis.  
Although much remains to be unraveled, the notion that mitochondrial function could be 
modulated by highly specialized domains at the ER-mitochondria interface is today generally 
accepted. More and more efforts will be made in future and other experimental work will be 
necessary to make it completely understood, so doing  novel possibilities will be opened to 
modulate downstream pathological conditions linked to cellular proliferation or metabolism.  
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